<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">86971</article-id><article-id pub-id-type="doi">10.7554/eLife.86971</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-307083"><name><surname>Tomas Bort</surname><given-names>Elena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7897-8891</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307084"><name><surname>Joseph</surname><given-names>Megan D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8313-8467</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-307085"><name><surname>Wang</surname><given-names>Qiaoying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307086"><name><surname>Carter</surname><given-names>Edward P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4499-1101</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-307087"><name><surname>Roth</surname><given-names>Nicolas J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-307088"><name><surname>Gibson</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307089"><name><surname>Samadi</surname><given-names>Ariana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307090"><name><surname>Kocher</surname><given-names>Hemant M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-307091"><name><surname>Simoncelli</surname><given-names>Sabrina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7089-7667</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-122325"><name><surname>McCormick</surname><given-names>Peter J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2225-5181</contrib-id><email>p.mccormick@qmul.ac.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-209402"><name><surname>Grose</surname><given-names>Richard P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4738-0173</contrib-id><email>r.p.grose@qmul.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>London Centre for Nanotechnology, University College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>Department of Chemistry, University College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e86971</elocation-id><history><date date-type="received" iso-8601-date="2023-02-14"><day>14</day><month>02</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-03-17"><day>17</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-10-24"><day>24</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.24.513477"/></event></pub-history><permissions><copyright-statement>© 2023, Tomas Bort et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Tomas Bort et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-86971-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-86971-figures-v2.pdf"/><abstract><p>Pancreatic ductal adenocarcinoma (PDAC) continues to show no improvement in survival rates. One aspect of PDAC is elevated ATP levels, pointing to the purinergic axis as a potential attractive therapeutic target. Mediated in part by highly druggable extracellular proteins, this axis plays essential roles in fibrosis, inflammation response, and immune function. Analyzing the main members of the PDAC extracellular purinome using publicly available databases discerned which members may impact patient survival. <italic>P2RY2</italic> presents as the purinergic gene with the strongest association with hypoxia, the highest cancer cell-specific expression, and the strongest impact on overall survival. Invasion assays using a 3D spheroid model revealed P2Y<sub>2</sub> to be critical in facilitating invasion driven by extracellular ATP. Using genetic modification and pharmacological strategies, we demonstrate mechanistically that this ATP-driven invasion requires direct protein-protein interactions between P2Y<sub>2</sub> and αV integrins. DNA-PAINT super-resolution fluorescence microscopy reveals that P2Y<sub>2</sub> regulates the amount and distribution of integrin αV in the plasma membrane. Moreover, receptor-integrin interactions were required for effective downstream signaling, leading to cancer cell invasion. This work elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential for therapeutic targeting.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>pancreatic cancer</kwd><kwd>purinergic signalling</kwd><kwd>invasion</kwd><kwd>DNA-PAINT</kwd><kwd>3D modelling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A27781</award-id><principal-award-recipient><name><surname>Carter</surname><given-names>Edward P</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A25137</award-id><principal-award-recipient><name><surname>Carter</surname><given-names>Edward P</given-names></name><name><surname>Grose</surname><given-names>Richard P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MRC0227</award-id><principal-award-recipient><name><surname>Tomas Bort</surname><given-names>Elena</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/T008709/1</award-id><principal-award-recipient><name><surname>Joseph</surname><given-names>Megan D</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000288</institution-id><institution>Royal Society</institution></institution-wrap></funding-source><award-id>DHF\R1\191019</award-id><principal-award-recipient><name><surname>Simoncelli</surname><given-names>Sabrina</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000288</institution-id><institution>Royal Society</institution></institution-wrap></funding-source><award-id>RGS\R2\202038</award-id><principal-award-recipient><name><surname>Simoncelli</surname><given-names>Sabrina</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/N014308/1</award-id><principal-award-recipient><name><surname>Roth</surname><given-names>Nicolas J</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011704</institution-id><institution>Pancreatic Cancer Research Fund</institution></institution-wrap></funding-source><award-id>Tissue Bank Grant</award-id><principal-award-recipient><name><surname>Kocher</surname><given-names>Hemant M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>New role of P2Y<sub>2</sub>-αV integrin interactions in ATP-driven pancreatic cancer cell invasion provides a potential anti-metastatic target for pancreatic cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>PDAC, which accounts for 90% of diagnosed pancreatic cancer cases, has the lowest survival rate of all common solid malignancies. Surgery is the only potentially curative treatment, yet more than 80% of patients present with unresectable tumors (<xref ref-type="bibr" rid="bib32">Kocher, 2023</xref>). Consequently, most patients survive less than six months after diagnosis, resulting in a five year survival rate of less than 5% when accounting for all disease stages (<xref ref-type="bibr" rid="bib3">Bengtsson et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Kocher, 2023</xref>). Despite continued efforts, this statistic has improved minimally in the past 50 years. Due to increasing incidence, late detection, and lack of effective therapies, pancreatic cancer is predicted to be the second most common cause of cancer-related deaths by 2040 (<xref ref-type="bibr" rid="bib55">Rahib et al., 2021</xref>).</p><p>Failure to significantly improve clinical management is mainly a result of chemoresistance (<xref ref-type="bibr" rid="bib49">Neuzillet et al., 2017</xref>), thus it is of vital importance to find new therapeutics that can improve patient survival. PDAC is characterized by its desmoplastic stroma, with dense fibrosis leading to impaired vascularisation and high levels of hypoxia (<xref ref-type="bibr" rid="bib33">Koong et al., 2000</xref>; <xref ref-type="bibr" rid="bib13">Di Maggio, 2016</xref>). Lack of oxygen leads to cellular stress and death, resulting in the release of purines such as ATP and adenosine into the tumor microenvironment (<xref ref-type="bibr" rid="bib18">Forrester and Williams, 1977</xref>; <xref ref-type="bibr" rid="bib51">Pellegatti et al., 2008</xref>). Extracellular ATP concentration in PDAC is 200-fold more than in normal tissue (<xref ref-type="bibr" rid="bib23">Hu et al., 2019</xref>), suggesting that purinergic signaling could represent an effective therapeutic target in pancreatic cancer.</p><p>The proteins underpinning purinergic signaling comprise several highly druggable membrane proteins involved in the regulation of extracellular purines, mainly ATP and adenosine (<xref ref-type="bibr" rid="bib7">Burnstock and Novak, 2012</xref>; <xref ref-type="bibr" rid="bib4">Boison and Yegutkin, 2019</xref>; <xref ref-type="bibr" rid="bib73">Yu et al., 2021</xref>). Extracellular ATP is known to promote inflammation (<xref ref-type="bibr" rid="bib34">Kurashima et al., 2012</xref>), growth (<xref ref-type="bibr" rid="bib31">Ko et al., 2012</xref>), and cell movement (<xref ref-type="bibr" rid="bib43">Martínez-Ramírez et al., 2016</xref>). Contrastingly, adenosine is anti-inflammatory and promotes immunosuppression (<xref ref-type="bibr" rid="bib57">Schneider et al., 2021</xref>). There are ongoing clinical trials in several cancers, including PDAC, for drugs targeting the ectonucleotidase CD73 (NCT03454451, NCT03454451) and adenosine receptor 2 A (NCT03454451) in combination with PD-1 checkpoint inhibitors and/or chemotherapy. However, a Phase II multi-cancer study evaluating an anti-CD73 and anti-PD-L1 combination was withdrawn due to minimal overall clinical activity (NCT04262388). This suggests that the oncogenic impact of purinergic signaling may act via pathways other than immunosuppression and highlights the need for the further mechanistic understanding of purinergic signaling in PDAC to exploit its full therapeutic potential.</p><p>Here, we combine bioinformatic, genetic, and drug-based approaches to identify a novel mechanism mediating ATP-driven invasion, uncovering a new therapeutic target in PDAC, a cancer of unmet clinical need. Beginning with an in-depth in silico analysis of the purinergic signaling transcriptome in PDAC, using publicly available patient and cell line databases, we build on bioinformatic data associating the purinergic receptor P2Y<sub>2</sub> with PDAC. After validating the expression of P2Y<sub>2</sub> in human PDAC, we focus on identifying the function of the receptor in cancer cells. In vitro data underline the importance of P2Y<sub>2</sub> as a strong invasive driver, using a 3D physio-mimetic model of invasion. Finally, using a super-resolution imaging technique, DNA-PAINT, we characterize the behavior of P2Y<sub>2</sub> in the membrane at the single molecule level, demonstrating the nanoscale distribution and interaction of this receptor with RGD-binding integrins in promoting pancreatic cancer invasion.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The PDAC extracellular purinome associates with patient survival, hypoxia score and cell phenotype</title><p>The extracellular purinome encompasses 23 main surface proteins, including pannexin 1, P2X ion channels, ectonucleotidases, and the P2Y, and adenosine GPCRs (<xref ref-type="bibr" rid="bib14">Di Virgilio et al., 2018</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Interrogating public databases, we determined which purinergic signaling genes significantly impact pancreatic cancer survival. First, we examined the pancreatic adenocarcinoma (PAAD) database from The Cancer Genome Atlas (TCGA; n=177 patients), analyzing overall survival hazard ratios based on purinergic signaling gene expression (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Expression of five purinergic genes correlated with decreased patient survival, with high <italic>P2RY2</italic> expression being associated with the highest hazard ratio (2.99, 95%, CI: 1.69–5.31, log-rank p=8.5 × 10<sup>–5</sup>). We then examined the mutational profile and mRNA expression level of purinergic genes in patients. Using cBioPortal (<xref ref-type="bibr" rid="bib20">Gao, 2013</xref>), we generated OncoPrints of purinergic signaling genes from PAAD TCGA samples (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), observing few genetic alterations in 0–3% of tumors and a heterogeneous percentage of tumors with high mRNA expression (z-score &gt;1) for each purinergic gene. PDAC molecular subtypes associated with purinergic signaling genes were varied (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In the Bailey model, most genes were related to the immunogenic subtype except for <italic>NT5E</italic>, <italic>ADORA2B</italic>, <italic>PANX1,</italic> and <italic>P2RY2</italic>, which are related to squamous (<xref ref-type="bibr" rid="bib1">Bailey et al., 2016</xref>). Collisson molecular subtyping showed several purinergic genes associated mostly with quasimesenchymal and exocrine subtypes (<xref ref-type="bibr" rid="bib12">Collisson et al., 2011</xref>). The Moffitt subtypes were not strongly associated with purinergic genes except for <italic>ADA</italic>, <italic>NT5E</italic>, <italic>P2RY6</italic>, <italic>P2RY2,</italic> and <italic>PANX1</italic> associated with the Basal subtype (<xref ref-type="bibr" rid="bib45">Moffitt et al., 2015</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Characterization of purinergic signaling in pancreatic adenocarcinoma.</title><p>(<bold>A</bold>) Purinergic signaling proteins and gene names. (<bold>B</bold>) Hazard ratios of overall survival were calculated using KMPlot and the pancreatic adenocarcinoma (PAAD) The Cancer Genome Atlas (TCGA) cohort (n=177) for different purinergic genes. Statistically significant hazard ratios (log-rank p-value) are highlighted in red for worse survival and in blue for better survival. (<bold>C</bold>) Heatmap of purinergic genes significantly correlated (<italic>q</italic>&lt;0.05) to high (purple) or low (light blue) Winter hypoxia scores in the PAAD TCGA data set. Overall survival status and overall survival in months are shown at the top, and samples are ranked using the Winter Hypoxia score (Generated with cBioPortal). (<bold>D</bold>) Differential expression analysis of 60 paired stromal and tumor tissue microdissections (GSE93326) showing significantly differentially expressed purinergic genes in stromal or tumor epithelial tissue. (<bold>E</bold>) Gene weights for purinergic genes representing the relevance of each gene to each cell type compartment, obtained from DECODER PDAC TCGA deconvolution analysis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Characterization of purinergic genes in pancreatic adenocarcinoma.</title><p>(<bold>A</bold>) Oncoprint from the pancreatic adenocarcinoma (PAAD) The Cancer Genome Atlas (TCGA) cohort was generated using cBioPortal. mRNA high and mRNA low represent Z-score values of &gt;1 or &lt; −1.(<bold>B</bold>) KMplot generated in cBioPortal for patients with high (red) vs low (blue) Winter hypoxia scores (<bold>C</bold>) Volcano plots for differential expression results of PAAD TCGA patient of high or low hypoxia scores using three different hypoxia signatures (Winter, Ragnum, and Buffa). (<bold>D</bold>) Heat map of purinergic mRNA expression data for different Pancreatic ductal adenocarcinoma (PDAC) cell lines from CCLE. (<bold>E</bold>) Comparison of normal versus tumor normalized transcripts per million (TPM) expression of purinergic genes. Data was obtained using GEPIA and PAAD TCGA and GTEx.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig1-figsupp1-v2.tif"/></fig></fig-group><p>PDAC is known for its hypoxic environment (<xref ref-type="bibr" rid="bib33">Koong et al., 2000</xref>; <xref ref-type="bibr" rid="bib74">Yuen and Díaz, 2014</xref>), which is associated with worse overall survival (p=0.002, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>); hypoxia can lead to cellular stress and death, resulting in the increase of extracellular purines (<xref ref-type="bibr" rid="bib18">Forrester and Williams, 1977</xref>). The Winter (<xref ref-type="bibr" rid="bib71">Winter et al., 2007</xref>), Ragnum (<xref ref-type="bibr" rid="bib54">Ragnum et al., 2015</xref>), and Buffa (<xref ref-type="bibr" rid="bib6">Buffa et al., 2010</xref>) hypoxia scores were used to examine the correlation between the expression of purinergic genes and hypoxia in the PAAD TCGA database (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Samples were divided into low (n=88) or high (n=89) hypoxia score, using the median hypoxia score to perform a differential expression analysis. CD73 (<italic>NT5E</italic>), adenosine A2B receptor (<italic>ADORA2B</italic>), and P2Y<sub>2</sub> (<italic>P2RY2</italic>) mRNA expression associated strongly with the high hypoxia score group for all three hypoxia scores (log<sub>2</sub> ratio &gt;0.5, FDR &lt; 0.0001). P2Y<sub>2</sub> had the highest log<sub>2</sub> ratio in all hypoxia signatures compared to other purinergic genes. With a more extensive gene signature, the Winter hypoxia score (99 genes) allowed for a more comprehensive relative hypoxia ranking of tumor samples, compared to Ragnum (32 genes) and Buffa (52 genes) signatures. Hence, we used cBioPortal (<xref ref-type="bibr" rid="bib20">Gao, 2013</xref>) to generate a transcriptomic heatmap of purinergic genes, ranked using the Winter hypoxia score and overlaid with overall survival data (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Taken together, these results show a direct correlation between Winter hypoxia score and decreased overall survival for high hypoxia score-related purinergic genes.</p><p>We hypothesized that genes related to high hypoxia scores would be expressed preferentially in the tumor cell compartment, as PDAC cells inhibit angiogenesis, causing hypo-vascularisation in the juxta-tumoral stroma (<xref ref-type="bibr" rid="bib13">Di Maggio, 2016</xref>). Mining published RNA-seq data from 60 paired PDAC samples of stroma and tumor microdissections (GSE93326) (<xref ref-type="bibr" rid="bib44">Maurer et al., 2019</xref>) and performing differential expression analysis, we observed that most genes related to high Winter hypoxia scores (<italic>P2RY2</italic>, <italic>ADORA2B,</italic> and <italic>NT5E</italic>) were expressed in the tumor epithelial tissue (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), except for <italic>PANX1</italic>, encoding for pannexin 1, which is involved in cellular ATP release (<xref ref-type="bibr" rid="bib2">Bao et al., 2004</xref>).</p><p>To elucidate the cell type-specific purinergic expression landscape, we used published data from TCGA PAAD compartment deconvolution, using DECODER (<xref ref-type="bibr" rid="bib52">Peng et al., 2019</xref>) to plot purinergic gene weights for each cell type compartment (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The findings recapitulated the cell specificity data obtained from tumor microdissection analysis (<xref ref-type="bibr" rid="bib44">Maurer et al., 2019</xref>; <xref ref-type="fig" rid="fig1">Figure 1D</xref>). Expression of purinergic genes in cancer cells was confirmed by plotting Z-scores of mRNA expression of PDAC cell lines from the cancer cell line encyclopedia (<xref ref-type="bibr" rid="bib21">Ghandi et al., 2019</xref>) (CCLE; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Moreover, the expression of purinergic genes in normal tissue from the Genotype-Tissue Expression (GTEx) database compared to cancer tissue (PAAD TCGA) also mimicked the results found with DECODER (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). <italic>P2RY2</italic>, encoding P2Y<sub>2</sub> - a GPCR activated by ATP and UTP, was shown to be the purinergic gene most highly associated with cancer cell-specific expression in all our independent analyses (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, E</xref>). <italic>P2RY2</italic> additionally showed the strongest correlation with all hypoxia scores (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Most importantly, of all purinergic genes, <italic>P2RY2</italic> expression had the biggest adverse impact on patient survival (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). These independent in silico analyses encouraged us to explore the influence of P2Y<sub>2</sub> on pancreatic cancer cell behavior.</p></sec><sec id="s2-2"><title><italic>P2RY2</italic> is expressed in cancer cells and causes cytoskeletal changes</title><p>To validate our bioinformatic findings, based on microdissections from a 60 patient cohort (GSE93326) and from the deconvolution of 177 PAAD tissues from the TCGA, we performed RNAscope on human PDAC samples. This corroborated P2Y<sub>2</sub> mRNA expression as being localized to the epithelial tumor cell compartment and not stroma, normal epithelium, or endocrine tissues (n=3, representative images of 2 different patients shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), matching our findings from larger publicly available cohorts, including P2Y<sub>2</sub> IHC data from 264 patients in the Renji cohort (<xref ref-type="bibr" rid="bib23">Hu et al., 2019</xref>). P2Y<sub>2</sub> is known to be expressed at low levels in normal tissues but interestingly RNAscope did not detect this. This data suggests (1) the lower limits of the technique compounded by the challenge of RNA degradation in pancreatic tissue and (2) supports that in tumor tissue where it was detected there was indeed overexpression of P2Y<sub>2</sub>, in line with the bioinformatic data. Interrogating single-cell P2Y<sub>2</sub> RNA expression in normal PDAC from <ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/">https://www.proteinatlas.org/</ext-link> (<xref ref-type="bibr" rid="bib30">Karlsson et al., 2021</xref>), expression was found at low levels in several cells types, for example in endocrine cells and macrophages (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Using GEPIA (<xref ref-type="bibr" rid="bib65">Tang et al., 2017</xref>), we analyzed PAAD TCGA and GTEx mRNA expression of tumor (n=179) and normal samples (n=171). Tumor samples expressed significantly higher (p&lt;0.0001) P2Y<sub>2</sub> mRNA levels compared to the normal pancreas (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Kaplan-Meier analysis from PAAD TCGA KMplot (<xref ref-type="bibr" rid="bib36">Lánczky and Győrffy, 2021</xref>) showed a significant decrease in median overall survival in patients with high P2Y<sub>2</sub> mRNA expression (median survival: 67.87 vs 17.27 months) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Expression of P2Y<sub>2</sub> is specific to cancer cells, correlated with decreased overall survival in patients, and drives cytoskeletal rearrangements.</title><p>(<bold>A</bold>) RNAscope in-situ hybridization of P2Y<sub>2</sub> mRNA expression (magenta) in tumor and matching normal adjacent tissue. (<bold>B</bold>) P2Y<sub>2</sub> mRNA expression in tumor (TCGA) and normal (GTEx) pancreatic tissue samples (*p&lt;0.0001). Graph generated using GEPIA. (<bold>C</bold>) Kaplan-Meier plot comparing patients with high vs low expression of P2Y<sub>2</sub> in the Pancreatic Adenocarcinoma (PAAD) The Cancer Genome Atlas (TCGA) cohort. Graph generated using KMplot. (<bold>D</bold>) Top result of a GSEA (performed with WebGestalt) of two different pancreatic adenocarcinoma patient cohorts (PAAD TCGA and PDAC CPTAC) for the PANTHER pathway functional database. (<bold>E</bold>) Incucyte images of the pancreatic cancer cell line AsPC-1 12 hr after treatment with 100 µM ATP alone or with 5 µM AR-C (P2Y<sub>2</sub> antagonist). Cells are transduced with Lifeact to visualize f-actin (green). (<bold>F</bold>) Schematic of the amino acid sequence of P2Y<sub>2</sub> showing an RGD motif in the first extracellular loop (image generated in <ext-link ext-link-type="uri" xlink:href="http://gpcrdb.org/">http://gpcrdb.org/</ext-link>). (<bold>G</bold>) IF staining of P2Y<sub>2</sub> (green), integrin αV (red), and DAPI (blue) in AsPC-1 cells showing colocalization of P2Y<sub>2</sub> and integrin αV (yellow).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>mRNA and protein expression of P2Y<sub>2</sub> in pancreatic ductal adenocarcinoma (PDAC) cells.</title><p>(<bold>A</bold>) RNAscope in-situ hybridization of a positive control (<italic>PPIB</italic>, Cyclophilin B), negative control (<italic>DapB</italic>), and P2Y<sub>2</sub> mRNA expression in a PDAC tissue slide showing tumor and normal adjacent tissue. (<bold>B</bold>) Single-cell expression of P2Y<sub>2</sub> in healthy pancreatic tissue from the Human Protein Atlas (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/ENSG00000175591-P2RY2/single+cell+type/pancreas">https://www.proteinatlas.org/ENSG00000175591-P2RY2/single+cell+type/pancreas</ext-link>). (<bold>C</bold>) Top four results of a GSEA (performed with WebGestalt) of two different pancreatic adenocarcinoma patient cohorts (PAAD TCGA and PDAC CPTAC) for the ‘Molecular Function’ Gene Ontology (GO) functional database. (<bold>D</bold>) Incucyte analysis of average object area related to the average cell area of AsPC-1 cells at different concentrations of ATP (error bars show standard deviation). (<bold>E</bold>) Incucyte images of AsPC-1 cells with different concentrations of AR-C with or without ATP. (<bold>F</bold>) IF staining of four different PDAC cell lines showing various levels of P2Y<sub>2</sub> (green) and integrin αV (red) protein expression. (<bold>G</bold>) The respective reads per kilobase of exon per million reads mapped (RPKM) from CCLE.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To predict P2Y<sub>2</sub> function in PDAC, we performed gene set enrichment analysis (GSEA) of high vs low mRNA expressing P2Y<sub>2</sub> tumor samples, divided by the median expression, for PAAD TCGA (n=177) and the PDAC Clinical Proteomic Tumor Analysis Consortium (CPTAC) (n=140) databases. The top gene set enriched in the PANTHER pathway database in both cohorts was the ‘integrin signaling pathway’ (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The top four enriched gene sets from the Gene Ontology ‘Molecular function’ functional database were associated with cell adhesion molecule binding, the cytoskeleton, protease binding, and extracellular matrix binding (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). As preliminary validation of the GSEA results in vitro, we used the PDAC cell line AsPC-1, transduced with Lifeact, a peptide that fluorescently labels filamentous actin structures (<xref ref-type="bibr" rid="bib56">Riedl et al., 2008</xref>), and monitored cell morphology using the Incucyte live-cell analysis system. Cells treated with ATP (100 µM) showed cytoskeletal rearrangements which were blocked by the selective P2Y<sub>2</sub> antagonist AR-C118925XX (AR-C; 5 µM; <xref ref-type="fig" rid="fig2">Figure 2E</xref>; <xref ref-type="bibr" rid="bib46">Muoboghare et al., 2019</xref>). Exposing cells to ATP at 100 µM resulted in the biggest change in cell area when testing six concentrations from 0.01 to 1000 µM (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). ATP-driven morphological changes were fully reversed at 5 X (5 µM) the IC<sub>50</sub> of AR-C (1 µM), while AR-C on its own had no effect on cell morphology (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>).</p><p>P2Y<sub>2</sub> is the only P2Y GPCR possessing an RGD motif, located in the first extracellular loop (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). P2Y<sub>2</sub> has been shown to interact with αV integrins through this RGD motif (<xref ref-type="bibr" rid="bib15">Erb et al., 2001</xref>), but the significance of this interaction has not been explored in cancer. Immunofluorescence (IF) showed colocalization of integrin αV and P2Y<sub>2</sub> in the PDAC cell lines AsPC-1 as well as PDAC cell lines with strong epithelial morphology, BxPC-3 and CAPAN-2, while MIA PaCa-2 cells showed low expression of both proteins, and PANC-1 showed high integrin αV and low P2Y<sub>2</sub>, matching CCLE data (<xref ref-type="fig" rid="fig2">Figure 2G</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F, G</xref>). We hypothesized that P2Y<sub>2,</sub> through its RGD motif, could engage αV integrins in cancer cells in the presence of ATP, leading to increased migration and invasion.</p></sec><sec id="s2-3"><title>Targeting P2Y<sub>2</sub> and its RGD motif decreases ATP-driven invasion in PDAC cell lines</title><p>To evaluate the impact of P2Y<sub>2</sub> in pancreatic cancer cell invasion, we used a 3D hanging drop spheroid model (<xref ref-type="bibr" rid="bib47">Murray et al., 2022</xref>). PDAC cell lines were combined with stellate cells in a ratio of 1:2 (<xref ref-type="bibr" rid="bib28">Kadaba et al., 2013</xref>), using an immortalized stellate cell line, PS-1 (<xref ref-type="bibr" rid="bib19">Froeling et al., 2009</xref>) to form spheres (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), recapitulating the ratios of the two biggest cellular components in PDAC. Stellate cells are crucial for successful hanging drop sphere formation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>) and cancer cell invasion (<xref ref-type="bibr" rid="bib47">Murray et al., 2022</xref>). Spheres were embedded in a Collagen type I and Matrigel mix and cultured for 48 hr until imaging and fixing (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Given that extracellular ATP concentration in tumors is in the hundred micromolar range (<xref ref-type="bibr" rid="bib51">Pellegatti et al., 2008</xref>), spheres were treated with P2Y<sub>2</sub> agonists ATP and UTP (100 µM). Both nucleotides increased invasion of the PDAC cell line AsPC-1 significantly compared to vehicle control (p&lt;0.0001 and p<italic>=</italic>0.0013, respectively), and this was blocked by the P2Y<sub>2</sub> selective antagonist AR-C (5 µM, p=0.0237, and p=0.0133; <xref ref-type="fig" rid="fig3">Figure 3B and C</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Treating spheres with AR-C on its own did not show significant effects on invasion (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Importantly, a non-hydrolyzable ATP (ATPγS;100 µM) showed similar effects to ATP, implicating ATP and not its metabolites as the cause of the invasion (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Of note, IF staining of PS-1 cells showed negligible expression of P2Y<sub>2</sub> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). To determine whether integrin association was necessary for ATP-driven invasion, we treated spheres with 10 µM cyclic RGDfV peptide (cRGDfV), which binds predominantly to αVβ3 to block integrin binding to RGD motifs (<xref ref-type="bibr" rid="bib29">Kapp et al., 2017</xref>), such as that in P2Y<sub>2</sub> (<xref ref-type="bibr" rid="bib24">Ibuka et al., 2015</xref>). cRGDfV treatment reduced ATP-driven motility significantly, both in 3D spheroid invasion assays (p&lt;0.0001) (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>) and in 2D Incucyte migration assays (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E, F</xref>) as did treatment with AR-C. To ensure that this behavior was not restricted to AsPC-1 cells, experiments were corroborated in the epithelial-like BxPC-3 cell line (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G, H</xref>; <xref ref-type="bibr" rid="bib63">Tan et al., 1986</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The RGD motif in P2Y<sub>2</sub> is required for extracellular ATP-driven cancer cell invasion.</title><p>(<bold>A</bold>) Schematic diagram of the hanging drop sphere model for 3D sphere invasion assays. (<bold>B</bold>) Bright field and fluorescent images of spheres formed using AsPC-1 cells (magenta) with a histone 2B (H2B) tagged with a red fluorescent protein (RFP) and the stellate cell line PS-1 (green) with H2B tagged with a green fluorescent protein (GFP). Middle panel shows AsPC-1 cells in spheres with a dotted line highlighting the central sphere area. Spheres were treated with vehicle control or 100 µM ATP alone or with 5 µM AR-C or 10 µM cRGDfV. The quantification is shown in (<bold>C</bold>) using SuperPlots, where each color represents a biological repeat (n=3) and the larger points represent the mean % Invasion for each repeat. (<bold>D</bold>) Quantification of spheres formed by AsPC-1 cells transfected with a control siRNA or P2Y<sub>2</sub> siRNA and treated with or without 100 µM ATP. (<bold>E</bold>) Bright field and fluorescent images of spheres formed by AsPC-1 cells subjected to CRISPR/Cas9 gene disruption using a control guide RNA (CTR<sup>CRISPR</sup>) or P2Y<sub>2</sub> guide RNAs (P2Y<sub>2</sub><sup>CRISPR</sup>) and treated with or without 100 µM ATP. Quantification in (<bold>F</bold>). (<bold>G, I</bold>) Bright field and fluorescent images of AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells or PANC-1 cells (respectively) transfected with wild-type <italic>P2RY2</italic> (P2Y<sub>2</sub><sup>RGD</sup>) or mutant <italic>P2RY2<sup>D97E</sup></italic> (P2Y<sub>2</sub><sup>RGE</sup>) treated with or without 100 µM ATP and its quantification in (<bold>H</bold>) and (<bold>J</bold>), respectively. Statistical analysis with Kuskal-Wallis multiple comparison tests.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Invasion and migration experiments in Pancreatic ductal adenocarcinoma (PDAC) cell lines.</title><p>(<bold>A</bold>) Hanging drop sphere with and without PS-1 cells. (<bold>B, C</bold>) Quantification of AsPC-1 spheres treated with 100 µM UTP or ATPγS (respectively) in the absence or together with 5 µM AR-C or 10 µM cRGDfV (n=3 biological replicates). (<bold>D</bold>) IF staining of P2Y<sub>2</sub> in AsPC-1 and PS-1 stellate cells. (<bold>E</bold>) Migration assay with AsPC-1 and 100 µM ATP in the absence or together with 5 µM AR-C or/and 10 µM cRGDfV and (<bold>F</bold>) its quantification (n=3 biological replicates, statistical analysis with one-way ANOVA, * <italic>p</italic> &lt; 0.5, **** <italic>p</italic> &lt; 0.0001, error bars show standard deviation). (<bold>G</bold>) 3D sphere invasion assay using BxPC-3 cells treated with 100 µM of ATP in the absence or together with 5 µM AR-C or/and 10 µM cRGDfV and (<bold>H</bold>) its quantification (n=3 biological replicates). (<bold>I</bold>) qPCR of P2Y<sub>2</sub> expression and western blot of siRNA treated cells (control siRNA and P2Y<sub>2</sub> targeting siRNA, n=3 biological replicates). (<bold>J</bold>) AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> spheres treated with or without 5 µM of AR-C (n=3 biological replicates). (<bold>K</bold>) P2Y<sub>2</sub> IF staining of AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells transfected with an empty vector, P2Y<sub>2</sub><sup>RGD</sup> or P2Y<sub>2</sub><sup>RGE</sup> plasmids. Statistical analysis of all invasion experiments with Kuskal-Wallis multiple comparison tests.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Labeled uncropped blot of <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86971-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Full unedited blot of <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86971-fig3-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To further verify that ATP-driven invasion was dependent on P2Y<sub>2</sub>, we silenced P2Y<sub>2</sub> expression in AsPC-1 cells using siRNA (<xref ref-type="fig" rid="fig3">Figure 3D</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I</xref>), abrogating the invasive response to ATP (p&lt;0.0001). P2Y<sub>2</sub> involvement in this phenomenon was confirmed by generating a P2Y<sub>2</sub> CRISPR-Cas9 AsPC-1 cell line (P2Y<sub>2</sub><sup>CRISPR</sup>), which displayed a significant decrease in invasion compared to a control guide RNA CRISPR cell line (CTR<sup>CRISPR</sup>) in both ATP-treated (p&lt;0.0001) and non-treated (p=0.0005) conditions (<xref ref-type="fig" rid="fig3">Figure 3F and E</xref>). Additionally, we tested the off-target effects of AR-C in AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> spheres and confirmed no significant difference in invasion compared to the control (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>). Together, these findings demonstrate that P2Y<sub>2</sub> is essential for ATP-driven cancer cell invasion.</p><p>To determine the importance of the RGD motif of P2Y<sub>2</sub> in ATP-driven invasion, we obtained a mutant P2Y<sub>2</sub> construct, where the RGD motif was replaced by RGE (P2Y<sub>2</sub><sup>RGE</sup>), which has less affinity for αV integrins (<xref ref-type="bibr" rid="bib15">Erb et al., 2001</xref>). This mutant was transfected into AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells and compared to cells transfected with wild-type P2Y<sub>2</sub> (P2Y<sub>2</sub><sup>RGD</sup>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1K</xref>). Only spheres containing P2Y<sub>2</sub><sup>RGD</sup> transfected cells demonstrated a rescue of the ATP-driven invasive phenotype (p&lt;0.0001; <xref ref-type="fig" rid="fig3">Figure 3G and H</xref>), with P2Y<sub>2</sub><sup>RGE</sup> spheres not responding to ATP treatment. To ensure this behavior was not influenced by off-target CRISPR effects, we repeated the experiment in PANC-1 cell line, which expresses very low levels of P2Y<sub>2,</sub> but high levels of integrin αV (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>, G). No ATP-driven invasion was observed in PANC-1 cells transfected with an empty vector (EV) or with P2Y<sub>2</sub><sup>RGE</sup> (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>). Only when transfecting PANC-1 cells with P2Y<sub>2</sub><sup>RGD</sup> was ATP-driven invasion observed (p&lt;0.0001). These results demonstrate that the RGD motif of P2Y<sub>2</sub> is required for ATP-driven cancer cell invasion.</p></sec><sec id="s2-4"><title>DNA-PAINT reveals RGD-dependent changes in P2Y<sub>2</sub> and integrin αV surface expression</title><p>To interrogate how P2Y<sub>2</sub> interacts with αV integrins, we examined the nanoscale organization of P2Y<sub>2</sub> and αV proteins under different treatment conditions using a multi-color quantitative super-resolution fluorescence imaging method, DNA-PAINT. DNA-PAINT is a single-molecule localization microscopy (SMLM) method based on the transient binding between two short single-stranded DNAs - the ‘imager’ and ‘docking’ strands. The imager strand is fluorescently labeled and freely diffusing in solution, whilst the docking strand is chemically coupled to antibodies targeting the protein of interest. For DNA-PAINT imaging of P2Y<sub>2</sub> and integrin αV, proteins were labeled with primary antibodies chemically coupled to orthogonal docking sequences featuring a repetitive (ACC)n or (TCC)n motif, respectively (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The benefit of such sequences is to increase the frequency of binding events, which in turn allows the use of relatively low imager strand concentrations without compromising overall imaging times, whilst achieving a high signal-to-noise ratio and single-molecule localization precision (<xref ref-type="bibr" rid="bib60">Strauss and Jungmann, 2020</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>DNA-PAINT super-resolution microscopy reveals ATP and RGD-dependent changes in the number and distribution of integrin αV and P2Y<sub>2</sub> molecules in the plasma membrane.</title><p>(<bold>A, B</bold>) Overview of the DNA-PAINT microscopy technique and qPAINT analysis pipeline. (<bold>C</bold>) Histogram of qPAINT indices for αV (blue) and P2Y<sub>2</sub> (red) single-molecule localization clusters. Solid lines represent multi-peak Gaussian fit. (<bold>D</bold>) Rendered DNA-PAINT images of AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells transfected with P2Y<sub>2</sub><sup>RGD</sup> or P2Y<sub>2</sub><sup>RGE</sup> with or without 100 µM of ATP and close-ups showing the protein maps reconstructed from DNA-PAINT localization maps of P2Y<sub>2</sub> (red) and integrin αV (cyan). The quantification of the number of proteins or protein clusters (&gt;3 proteins) in each region of interest (ROI) are for P2Y<sub>2</sub> (red) (<bold>E</bold>) and (<bold>F</bold>), respectively and integrin αV (cyan) (<bold>G</bold>) and (<bold>H</bold>), respectively. Quantification of protein proximity using the nearest neighbor distance (NND), with the percentages of integrin αV and P2Y<sub>2</sub> proteins being &lt;50 nm apart (<bold>I</bold>), between different αV integrins being 20–100 nm (<bold>J</bold>) or &lt;20 nm (<bold>K</bold>) apart; and P2Y<sub>2</sub> from other P2Y<sub>2</sub> proteins being &lt;40 nm apart (<bold>H</bold>). Statistical analysis with Kuskal-Wallis multiple comparison test of 21 4x4 µm ROIs from a minimum of 5 cell regions per condition.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Quantification of P2Y2 and integrin αV at the membrane using DNA-PAINT.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Schematic diagram of nearest neighbor distance (NND) distances and NND histograms.</title><p>(<bold>A</bold>) Schematic diagram of the predicted maximum distance between fluorescent molecules indicating physical contact between proteins, to the nearest first significant figure. (<bold>B</bold>) Histograms of the nearest neighbor distance between proteins vs the frequency of occurrence for AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> in different conditions (solid line, strong color) or randomly computer-generated controls (dotted line, light color).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig4-figsupp2-v2.tif"/></fig></fig-group><p>The repetitive binding of imager and docking DNA strands in DNA-PAINT causes the same protein to be detected multiple times with nearly identical coordinates, originating a cluster of single-molecule localization around the true position of the protein. In contrast to other SMLM approaches, it is possible to take advantage of the DNA-binding kinetics to stoichiometrically calculate the number of proteins detected in each cluster of single molecule localizations, via an approach known as qPAINT (<xref ref-type="bibr" rid="bib58">Schnitzbauer et al., 2017</xref>). As exemplified in <xref ref-type="fig" rid="fig4">Figure 4B</xref> (and detailed in the methods section), qPAINT relies on the first-order binding kinetics between the individual imager and docking strands to determine the number of copies of a protein that reside within a cluster of single-molecule localizations. The qPAINT index histograms obtained from P2Y<sub>2</sub> and αV DNA-PAINT data sets were fitted with a multi-peak Gaussian function, identifying peaks located at multiples of a qPAINT index value of <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> 0.011 Hz and 0.009 for the P2Y<sub>2</sub> and αV docking-imager pairs, respectively (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). These values were thus used to quantify the exact number of P2Y<sub>2</sub> and αV proteins in all the clusters of single-molecule localization in the DNA-PAINT data sets. By combining qPAINT with spatial statistics, we recovered a good estimation of the ground truth position of all the proteins in the DNA-PAINT data and quantified protein clustering.</p><p>We have previously analyzed GPCR oligomerization quantitatively using DNA-PAINT super-resolution microscopy of P2Y<sub>2</sub> in AsPC-1 cells (<xref ref-type="bibr" rid="bib26">Joseph et al., 2021</xref>), where we observed a decrease in P2Y<sub>2</sub> oligomerization upon AR-C treatment. Hence, we questioned whether the RGD motif in P2Y<sub>2</sub> affected receptor distribution and clustering. We imaged AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells transfected with P2Y<sub>2</sub><sup>RGD</sup> or P2Y<sub>2</sub><sup>RGE</sup> in the absence or presence of 100 µM ATP for 1 hr (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), observing a 42% decrease in the median density of P2Y<sub>2</sub> proteins at the membrane when P2Y<sub>2</sub><sup>RGD</sup> cells were treated with ATP, compared to control (p&lt;0.0001; <xref ref-type="fig" rid="fig4">Figure 4E</xref>). In contrast, although a slight decrease in the density of P2Y<sub>2</sub> proteins on P2Y<sub>2</sub><sup>RGE</sup> cells was observed following ATP treatment, this was not statistically significant (p=0.1570). The density of P2Y<sub>2</sub> proteins and protein clusters in both P2Y<sub>2</sub><sup>RGD</sup> and P2Y<sub>2</sub><sup>RGE</sup> controls were equivalent (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>; p&gt;0.9999), indicating similar expression of the receptor at the surface in both control conditions. Interestingly, the density of P2Y<sub>2</sub> clusters decreased significantly in both conditions when treated with ATP (<xref ref-type="fig" rid="fig4">Figure 4F</xref>; 43% decrease, p&lt;0.0001 for P2Y<sub>2</sub><sup>RGD</sup>, and 48% decrease, p=0.0002 for P2Y<sub>2</sub><sup>RGE</sup>). We repeated these studies with normal AsPC-1 cells (untransfected and with unaltered P2Y<sub>2</sub> expression) treated with ATP +/-cRGDfV, only observing a reduction of P2Y<sub>2</sub> at the membrane with ATP alone (68% decrease, p&lt;0.0001), while co-treatment with cRGDfV prevented this change (p&gt;0.9999; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>). These findings highlight that the RGD motif is required for αV integrin to control P2Y<sub>2</sub> levels at the membrane.</p><p>Turning to αV integrins, we observed an increase in the density of αV molecules and αV clusters at the membrane when stimulating P2Y<sub>2</sub><sup>RGD</sup> with ATP (165 αV molecules/ROI, IQR = 162.75; 6.5 αV clusters/ROI, IQR = 8.75) compared to P2Y<sub>2</sub><sup>RGD</sup> without stimulation (58 αV molecules/ROI, IQR = 41; 2.5 αV clusters/ROI, IQR = 2; p=0.0003; <xref ref-type="fig" rid="fig4">Figure 4G and H</xref>). This phenomenon was also observed with normal AsPC-1 cells, with significantly more αV molecules and clusters (p=0.0382 and p=0.0349) detected following ATP stimulation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C, D</xref>). In absence of stimulation, P2Y<sub>2</sub><sup>RGE</sup> transfected cells exhibited more αV molecules and clusters at the membrane (182 αV molecules/ROI, IQR = 262.75; 9 αV clusters/ROI IQR = 14) compared to P2Y<sub>2</sub><sup>RGD</sup> cells (p=0.0003, p=0.0024, respectively). However, treating P2Y<sub>2</sub><sup>RGE</sup> cells with ATP did not result in significant changes in αV molecules and clusters (p=0.7086; p=0.1846). When the number of clusters was normalized with the number of αV molecules, to obtain the percentage of αV in clusters (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>), there was no significant difference between conditions (p&gt;0.9999), indicating that the increase in the number of αV clusters was due to an increase in the number of αV proteins at the membrane. Of note, the percentage of P2Y<sub>2</sub> clusters significantly decreased in P2Y<sub>2</sub><sup>RGE</sup> cells when treated with ATP compared to all other conditions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>). Taken together, these data indicate an RGD motif-dependent function of activated P2Y<sub>2</sub> in localizing integrin αV to the membrane.</p><p>Nearest neighbor distance (NND) was used to analyze homo and heterotypic protein-protein interactions between P2Y<sub>2</sub> and αV. NND ranges were selected by using the approximate dimension of the antibodies (~14 nm) (<xref ref-type="bibr" rid="bib64">Tan, 2008</xref>), integrins (5–10 nm) (<xref ref-type="bibr" rid="bib37">Lepzelter et al., 2012</xref>), and GPCRs (~3 nm) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>) and corroborating them with the NND histograms (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>) to predict the NND range in nm indicating a protein-protein interaction. We detected a higher percentage of integrin αV proteins in &lt;50 nm proximity to P2Y<sub>2</sub> in P2Y<sub>2</sub><sup>RGD</sup> cells following ATP stimulation (<xref ref-type="fig" rid="fig4">Figure 4I</xref>; 103% increase, p=0.0143). In contrast, P2Y<sub>2</sub><sup>RGE</sup> cells stimulated with ATP showed a 43% decrease (p=0.0101) in αV molecules in close proximity to P2Y<sub>2</sub> in comparison to unstimulated cells. Analyzing the percentage of αV proteins with NND in the 20–100 nm range, we saw a similar pattern (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). ATP-stimulated P2Y<sub>2</sub><sup>RGD</sup> and unstimulated P2Y<sub>2</sub><sup>RGE</sup> cells showed an increased percentage of αV proteins spaced at this range compared to untreated P2Y<sub>2</sub><sup>RGD</sup> cells (98% increase with p=0.0132 and 89% increase with p=0.0181). No significant changes were observed in NND of &lt;20 nm between αV proteins in any of the conditions (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). In contrast, P2Y<sub>2</sub><sup>RGD</sup> molecules were in significantly closer proximity to each other compared to P2Y<sub>2</sub><sup>RGE</sup> in control and stimulated conditions (p&lt;0.0001 and p=0.007) (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). In summary, our SMLM studies demonstrate a reciprocal interaction between αV integrin and P2Y<sub>2</sub> receptors, where P2Y<sub>2</sub> can alter integrin localization to the plasma membrane while αV integrins influence activated P2Y<sub>2</sub> membrane localization.</p></sec><sec id="s2-5"><title>The RGD motif in P2Y<sub>2</sub> is involved in integrin signaling</title><p>There is growing evidence of the importance of endosomal GPCR signaling and its potential relevance in disease and therapeutic opportunities (<xref ref-type="bibr" rid="bib8">Calebiro and Godbole, 2018</xref>). As we identified the RGD motif in P2Y<sub>2</sub> having a possible role in receptor internalization, integrin dynamics, and invasion, we proceeded to look at integrin signaling through phosphorylation of FAK (p-FAK) and ERK (p-ERK) from 0 to 1 hr after treating with 100 µM ATP. AsPC-1 cells displayed a significant increase of FAK and ERK phosphorylation after 15 min of ATP stimulation, which was abrogated by concomitant targeting of P2Y<sub>2</sub> with AR-C (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). When impairing the RGD motif function in P2Y<sub>2</sub> with cRGDfV or by transfecting AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells with the P2Y<sub>2</sub><sup>RGE</sup> mutant, p-FAK, and p-ERK levels decreased (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Collectively, targeting the RGD motif in P2Y<sub>2</sub> impairs receptor signaling and inhibits pancreatic cancer cell invasion.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The RGD motif in P2Y<sub>2</sub> is involved in FAK/ERK signaling.</title><p>(<bold>A, B</bold>) Western blots of phosphorylated FAK (p-FAK) and ERK (p-ERK) of AsPC-1 cells treated with ATP or pre-treated for 30 min with AR-C (5 µM) or cRGDfV (10 µM), respectively and treated with ATP for 60 min. (<bold>C</bold>) Western blot of AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells transfected with P2Y<sub>2</sub><sup>RGD</sup> or P2Y<sub>2</sub><sup>RGE</sup> and treated with ATP for 60 min. Representative images of three biological replicates.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Labeled uncropped blots of <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86971-fig5-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Full unedited blots of <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86971-fig5-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig5-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Improved molecular understanding of PDAC is vital to identify effective therapeutic approaches to improve patient survival. Purinergic signaling includes many druggable targets that have been related to hypoxia (<xref ref-type="bibr" rid="bib61">Synnestvedt et al., 2002</xref>), immunosuppression (<xref ref-type="bibr" rid="bib17">Fong et al., 2020</xref>), and invasion (<xref ref-type="bibr" rid="bib38">Li et al., 2015</xref>), but have been relatively underexplored in PDAC. In this study, we used publicly available databases to identify purinergic signaling genes that could be promising targets for PDAC, determining P2Y<sub>2</sub> as a driver of pancreatic cancer cell invasion. Extracellular ATP stimulated invasion in a 3D spheroid model of PDAC; an effect blocked by targeting P2Y<sub>2</sub> genetically and pharmacologically. Mechanistically, we identified that the RGD motif in the first extracellular loop of P2Y<sub>2</sub> is required for ATP-driven cancer invasion. Importantly, quantitative DNA-PAINT super-resolution fluorescence microscopy revealed the role of this RGD motif in orchestrating the number of P2Y<sub>2</sub> and αV integrin proteins at the plasma membrane, upon ATP stimulation.</p><p>Purinergic signaling has been associated classically with hypoxia and immune function in cancer (<xref ref-type="bibr" rid="bib14">Di Virgilio et al., 2018</xref>). One of the first reports of hypoxia-inducing ATP release in cells identified an increase of extracellular ATP in rat heart cells when kept in hypoxic conditions (<xref ref-type="bibr" rid="bib18">Forrester and Williams, 1977</xref>). PDAC is a highly hypoxic cancer, with high levels of ATP reported in the tumor interstitial fluid of human and mouse PDAC tissues compared to healthy tissues (<xref ref-type="bibr" rid="bib23">Hu et al., 2019</xref>). This vast release of ATP results in immune-mediated inflammatory responses via immune cells expressing purinergic signaling receptors (<xref ref-type="bibr" rid="bib10">Chiarella et al., 2021</xref>). Expression of most purinergic genes was associated predominantly with immune cells, immunogenic PDAC subtype, and low hypoxia scores (<xref ref-type="fig" rid="fig1">Figure 1C and E</xref>). In contrast, expression of genes correlated with worse survival and hypoxia (<italic>PANX1</italic>, <italic>NT5E</italic>, <italic>ADORA2B,</italic> and <italic>P2RY2</italic>) was associated with tumor cells and the squamous PDAC subtype, correlating with hypoxia, inflammation, and worse prognosis (<xref ref-type="bibr" rid="bib1">Bailey et al., 2016</xref>). The role of CD73 in PDAC has been examined in several studies (<xref ref-type="bibr" rid="bib73">Yu et al., 2021</xref>) (NCT03454451, NCT03454451). In contrast, the adenosine A<sub>2B</sub> receptor has not been well studied. Adenosine A<sub>2B</sub> receptor requires larger agonist concentrations for activation compared to other receptors in the same family, such as adenosine A<sub>2A</sub> (<xref ref-type="bibr" rid="bib5">Bruns et al., 1986</xref>; <xref ref-type="bibr" rid="bib72">Xing et al., 2016</xref>), and receptor expression has been reported to increase when cells are subjected to hypoxia (<xref ref-type="bibr" rid="bib16">Feoktistov et al., 2004</xref>). Moreover, HIF-1α has been shown to upregulate A<sub>2B</sub> and P2Y<sub>2</sub> expression in liver cancer (<xref ref-type="bibr" rid="bib62">Tak et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Kwon et al., 2019</xref>). From our analyses, P2Y<sub>2</sub> was associated with the worst patient overall survival, highest patient hypoxia scores, and strongest correlation with cancer cell expression compared to other purinergic genes. These observations were supported by published immunohistochemical staining of 264 human PDAC samples, showing that P2Y<sub>2</sub> localized predominantly in cancer cells in human PDAC and that P2Y<sub>2</sub> activation with ATP led to elevated HIF-1α expression (<xref ref-type="bibr" rid="bib23">Hu et al., 2019</xref>). Hence, we decided here to explore P2Y<sub>2</sub> in greater depth.</p><p>P2Y<sub>2</sub> has been associated with cancer cell growth and glycolysis in PDAC (<xref ref-type="bibr" rid="bib31">Ko et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Hu et al., 2019</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2020</xref>). Combination treatment of subcutaneous xenografts of AsPC-1 or BxPC-3 cells with the P2Y<sub>2</sub> antagonist AR-C together with gemcitabine significantly decreased tumor weight and resulted in increased survival compared to placebo or gemcitabine monotherapy control (<xref ref-type="bibr" rid="bib23">Hu et al., 2019</xref>). Surprisingly, GSEA results of two different cohorts suggested a possible additional function of P2Y<sub>2</sub> in invasion. Increased glycolysis and cytoskeletal rearrangements have been linked (<xref ref-type="bibr" rid="bib50">Park et al., 2020</xref>), and both events could occur downstream of P2Y<sub>2</sub> activation. P2Y<sub>2</sub> has been implicated in invasive phenotypes in prostate, breast, and ovarian cancer (<xref ref-type="bibr" rid="bib25">Jin et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Li et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Martínez-Ramírez et al., 2016</xref>). Moreover, high P2Y<sub>2</sub> expression in patients was related to integrin signaling. The RGD motif in the first extracellular loop of P2Y<sub>2</sub> results in a direct interaction of P2Y<sub>2</sub> with RGD-binding integrins, particularly integrins αVβ3 and αVβ5 (<xref ref-type="bibr" rid="bib15">Erb et al., 2001</xref>; <xref ref-type="bibr" rid="bib24">Ibuka et al., 2015</xref>). This interaction can exert phenotypic effects – for example, the binding of P2Y<sub>2</sub> to integrins via its RGD motif is necessary for tubule formation in epithelial intestinal cell line 3D models (<xref ref-type="bibr" rid="bib24">Ibuka et al., 2015</xref>). We focus here on the importance of the RGD motif of P2Y<sub>2</sub> and its key for integrin interaction in a cancer context. We were able to abrogate ATP-driven invasion using either the P2Y<sub>2</sub> selective antagonist AR-C or by blocking P2Y<sub>2</sub>-integrin complexes using the selective αVβ3 cyclic RGD-mimetic peptide inhibitor cRGDfV. Likewise, spheres made using ASPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> or PANC-1 cells transfected with mutant P2Y<sub>2</sub><sup>RGE</sup>, which decreases the affinity of P2Y<sub>2</sub> for integrins, did not invade in response to ATP stimulation. Altogether, these results (1) support P2Y<sub>2</sub> involvement in PDAC cell invasion, (2) show the RGD motif is essential for this function, and (3) identify the mechanism for this to be caused by P2Y<sub>2</sub>-integrin complexes. Despite efforts, there are currently no clinically efficacious P2Y<sub>2</sub> antagonists, with poor oral bioavailability and low selectivity being major issues (<xref ref-type="bibr" rid="bib48">Neumann et al., 2022</xref>). Our findings demonstrate that P2Y<sub>2</sub> can also be targeted by blocking its interaction with RGD-binding integrins, due to its dependence on integrins for its pro-invasive function.</p><p>GPCR-integrin crosstalk is involved in many biological processes (<xref ref-type="bibr" rid="bib69">Wang et al., 2005</xref>; <xref ref-type="bibr" rid="bib66">Teoh et al., 2012</xref>). Only one study has directly examined the spatial distribution of integrins and GPCRs, however, this relied on IF analysis (<xref ref-type="bibr" rid="bib15">Erb et al., 2001</xref>), where only changes in the micron scale will be perceived, hence losing information on the nanoscale distances and individual protein interactions. Here, we present a method to image integrin and GPCR dynamics using quantitative DNA-PAINT super-resolution fluorescence microscopy (<xref ref-type="bibr" rid="bib58">Schnitzbauer et al., 2017</xref>), allowing spatial and quantitative assessment of P2Y<sub>2</sub> and integrin αV interactions at the single protein level. Following ATP stimulation, the number of P2Y<sub>2</sub> proteins at the plasma membrane decreased significantly after 1 hr, implying receptor internalization, in line with previous work showing P2Y<sub>2</sub> at the cell surface was reduced significantly after 1 hr of UTP stimulation (<xref ref-type="bibr" rid="bib67">Tulapurkar et al., 2005</xref>). Of note, cytoskeletal rearrangements, which we have also observed upon ATP stimulation (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), were required for P2Y<sub>2</sub> clathrin-mediated internalization, and authors noted that P2Y<sub>2</sub> was most likely in a complex with integrins and extracellular matrix-binding proteins. Cells expressing RGE mutant P2Y<sub>2</sub> or treated with cRGDfV, did not show significant changes in P2Y<sub>2</sub> levels at the membrane upon ATP treatment, thus implicating the RGD motif in P2Y<sub>2</sub> in agonist-dependent receptor internalization, though we have focused on motility phenotype in this work.</p><p>P2Y<sub>2</sub> affecting cell surface redistribution of αV integrin has been reported, with αV integrin clusters observed after 5 min stimulation with UTP (<xref ref-type="bibr" rid="bib11">Chorna et al., 2007</xref>). We observed an increased number of αV integrin molecules and clusters 1 hr after ATP stimulation, although this increase in clusters was mainly due to the increase in the total number of αV integrins at the membrane. The distance between αV integrin and P2Y<sub>2</sub> molecules decreased (NND &lt;50 nm) with ATP stimulation, indicating possible interaction. In contrast, with mutant P2Y<sub>2</sub><sup>RGE</sup>, no significant ATP-dependent changes in the number of P2Y<sub>2</sub> or αV integrin proteins at the membrane were observed. The same phenomenon was observed when treating normal AsPC-1 cells (untransfected and with no alteration to P2Y<sub>2</sub>) with cRGDfV and ATP. We speculate that by reducing the ability of integrins to bind to the RGD of P2Y<sub>2</sub>, through receptor internalization, RGE mutation or through cRGDfV treatment, there is less RGD-triggered integrin endocytosis, hence less integrin recycling and an increase of integrins at the cell surface. Western blot results supported our postulated role of the RGD motif in P2Y<sub>2</sub> regulating downstream integrin signaling through FAK and ERK, leading to cancer cell migration and invasion (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>). This is the first single-molecule super-resolution study to explore integrin and GPCR dynamics and to demonstrate a requirement for integrin-P2Y<sub>2</sub> interactions in cancer cell invasion.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Proposed mechanism of P2Y<sub>2</sub> and integrin interactions in pancreatic cancer invasion.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-fig6-v2.tif"/></fig><p>In summary, our study demonstrates that P2Y<sub>2</sub>, via its RGD motif, has a pivotal role in ATP-induced PDAC invasion by interacting with and regulating the number of αV integrins at the plasma membrane, revealing this critical axis as a promising therapeutic target.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Data mining and bioinformatic analysis</title><p>Hazard ratios and the P2Y<sub>2</sub> Kaplan-Meier plot for overall survival were obtained using Kaplan-Meier Plotter (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018753">SCR_018753</ext-link>) (<xref ref-type="bibr" rid="bib36">Lánczky and Győrffy, 2021</xref>) and the pancreatic adenocarcinoma dataset from the cancer genome atlas (PAAD TCGA, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003193">SCR_003193</ext-link>).</p><p>Using cBioPortal (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014555">SCR_014555</ext-link>) (<xref ref-type="bibr" rid="bib20">Gao, 2013</xref>) and the database PAAD TCGA, mRNA differential expression analysis was performed for each Hypoxia Score (<xref ref-type="bibr" rid="bib71">Winter et al., 2007</xref>; <xref ref-type="bibr" rid="bib6">Buffa et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Ragnum et al., 2015</xref>) by separating patients using the median hypoxia score. Results from purinergic genes were plotted in a volcano plot using VolcaNoseR (<xref ref-type="bibr" rid="bib22">Goedhart and Luijsterburg, 2020</xref>). Significant hits were plotted in a heat map using cBioPortal (<xref ref-type="bibr" rid="bib20">Gao, 2013</xref>). RNAseq raw counts from stromal and epithelial PDAC tissue from microdissections were downloaded from the GEO database (GSE93326) (<xref ref-type="bibr" rid="bib44">Maurer et al., 2019</xref>) and a differential expression analysis was performed using DESeq2 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link>) (<xref ref-type="bibr" rid="bib42">Love et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Varet et al., 2016</xref>) in R.</p><p>Gene weight results from DECODER from PDAC tissues in the TCGA database were obtained from published results (<xref ref-type="bibr" rid="bib52">Peng et al., 2019</xref>). Using GEPIA (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018294">SCR_018294</ext-link>) (<xref ref-type="bibr" rid="bib65">Tang et al., 2017</xref>), mRNA expression of purinergic genes in normal tissue from the Genotype-Tissue Expression (GTEx, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013042">SCR_013042</ext-link>) compared to cancer tissue (PAAD TCGA) was obtained. PDAC cell line mRNA z-scores or mRNA reads per kilobase million (RPKM) were obtained using cBioPortal and the Cancer Cell Line Encyclopaedia (CCLE, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013836">SCR_013836</ext-link>) data (<xref ref-type="bibr" rid="bib20">Gao, 2013</xref>).</p><p>For gene set enrichment analysis (GSEA), cBioPortal was used to separate PAAD TCGA or PDAC CPTAC patients into high and low <italic>P2RY2</italic> by <italic>P2RY2</italic> median expression and perform the differential expression analysis. Log ratio values were inserted in the WEB-based Gene SeT AnaLysis Toolkit (WebGestalt, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006786">SCR_006786</ext-link>) (<xref ref-type="bibr" rid="bib39">Liao et al., 2019</xref>), where ‘GO: Molecular Function’ or ‘Panther’ with default analysis parameters were selected.</p></sec><sec id="s4-2"><title>RNAscope in-situ hybridization</title><p>Formalin-fixed paraffin-mbedded (FFPE) sections (n=3) of PDAC with stroma and normal adjacent tissue were obtained from the Barts Pancreas Tissue Bank (Project 2021/02/QM/RG/E/FFPE). Sections were stained using the human <italic>P2RY2</italic> probe (853761, ACD) and the RNAscope 2.5 HD Assay-RED (ACD) following the manufacturer’s instructions. Slides were imaged by NanoZoomer S210 slide scanner (Hamamatsu).</p></sec><sec id="s4-3"><title>Cell lines and cell culture</title><p>The pancreatic cancer cell lines AsPC-1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0152">CVCL_0152</ext-link>), BxPC-3 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0186">CVCL_0186</ext-link>), MIA PaCa-2 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0428">CVCL_0428</ext-link>) and PANC-1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0480">CVCL_0480</ext-link>), in addition to the immortalized stellate cell line PS-1 (<xref ref-type="bibr" rid="bib19">Froeling et al., 2009</xref>) were kindly donated by Prof. Hemant Kocher (Queen Mary University of London). Cell lines stably expressing fluorescently labeled histone subunits (H2B) or Lifeact (<xref ref-type="bibr" rid="bib56">Riedl et al., 2008</xref>) were transduced with viral supernatant obtained from HEK293T cells co-transfected with pCMVR8.2 (Addgene #12263) and pMD2.G (Addgene #12259) packaging plasmids, and either H2B-GFP (Addgene #11680), H2B-RFP (Addgene #26001), or Lifeact-EGFP (Addgene # 84383) plasmids using FuGENE transfection reagent (Promega), following manufacturer’s guidelines. Successfully transduced cells were isolated using a BD FACS Aria Fusion cell sorter. AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells were generated by transfecting cells with a dual gRNA (<named-content content-type="sequence">TGAAGGGCCAGTGGTCGCCGCGG</named-content> and <named-content content-type="sequence">CATCAGCGTGCACCGGTGTCTGG</named-content>)CRISPR-CAS9 plasmid (VectorBuilder) with an mCherry marker which was used to select successfully transfected cells as above. Clonal expansion of single sorted cells was achieved with serial dilution cloning. Clones were evaluated by IF for P2Y<sub>2</sub> compared to parental AsPC-1 cells. Cell lines were grown at 37 °C with 5% CO<sub>2</sub> in DMEM (Gibco), RPMI-1640 (Gibco), or DMEM/F-12 (Sigma) supplemented with 10% fetal bovine serum (Sigma). Cells were monitored for mycoplasma contamination every six months.</p></sec><sec id="s4-4"><title>Cell fixation and immunofluorescent staining</title><p>Cells were seeded on coverslips placed in a six well-plate (Corning) and fixed the next day in 4% paraformaldehyde (LifeTech) for 30 min and washed 3 x with phosphate-buffered saline (PBS). Coverslips were placed in 0.1% Triton X-100 (Avantor) for 10 min for permeabilization, followed by three PBS washes and blocking with 5% bovine serum albumin (BSA; Merck) for 1 hr. Coverslips were incubated at 4 °C overnight with anti-P2Y<sub>2</sub> (APR-010, Alomone labs) and anti-integrin αV antibodies (P2W7, Santa Cruz) diluted in blocking solution (1:100 and 1:200, respectively). After three PBS washes, coverslips were incubated for 1 hr with Alexa Fluor 647 goat anti-mouse and Alexa Fluor 488 goat anti-rabbit (Invitrogen) or Alexa Fluor 546 goat anti-rabbit at 1:1000, diluted in blocking buffer. Following three PBS washes, 4’,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) was used as a nuclear stain and was incubated for 10 min. Slides were mounted using Mowiol (Calbiochem) and imaged 24 hr later using a LSM 710 confocal microscope (Zeiss).</p></sec><sec id="s4-5"><title>siRNA and plasmid transfection</title><p>Cells were seeded in six well plates at a density of 200,000 cells/well 24 hr before transfection. For siRNA experiments, cells were transfected with 20 nM pooled control or P2Y<sub>2</sub>-targeting siRNAs from a siGENOME SMARTpool (Dharmacon, GE Healthcare) with Lipofectamine 3000 (Invitrogen) following the manufacturer’s instructions. For P2Y<sub>2</sub> plasmid expression experiments, cells were transfected with 500 nM <italic>P2RY2</italic> (P2Y<sub>2</sub><sup>RGD</sup>) or <italic>P2RY2D97E</italic> (P2Y<sub>2</sub><sup>RGE</sup>) in pcDNA3.1 vector (Obtained from GenScript) or pcDNA3.1 alone (Empty vector, EV) together with lipofectamine 3000 and p3000 reagent (Invitrogen) as per manufacturer’s instructions. Plasmid concentration was selected by comparing AsPC-1 IF staining of P2Y<sub>2</sub> with IF staining in AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> and PANC-1 cells with different concentrations of the plasmid to achieve a similar IF signal. Cells were split 48 hr post-transfection for experiments or imaged 72 hr post-transfection.</p></sec><sec id="s4-6"><title>3D sphere model invasion assay</title><p>Spheres of PDAC cell lines with PS-1 cells were generated as described (<xref ref-type="bibr" rid="bib47">Murray et al., 2022</xref>). Cancer cells at 22,000 cells/mL and PS-1 cells at 44,000 cells/mL were combined with DMEM/F-12 and 1.2% methylcellulose in a 4:1 ratio of methylcellulose (Sigma-Aldrich) and 20 µl drops, each containing 1000 cells, pipetted on the underside of a 15 cm dish lid (Corning) and hanging drops were incubated overnight at 37 °C. The next day, spheres were collected and centrifuged at 300 g for 4 min and washed with the medium. A mix of 2 mg/mL collagen (Corning), 175 µL/mL Matrigel, 25 µL/mL HEPES (1 M, pH 7.5), and 1 N NaOH (for neutral pH correction) was prepared with DMEM/F12 medium. Spheroids were re-suspended and seeded in low attachment 96-well plates (50 µl per well) with 40 µL previously gelled mix in the bottom of the wells. Once set, 150 µL of DMEM/F12 was added with treatments. Spheres were treated with 100 µM adenosine 5’-triphosphate trisodium salt hydrate (ATP, Sigma), uridine 5’-triphosphate trisodium salt hydrate (UTP, Sigma) or adenosine 5’-[γ-thio]triphosphate tetralithium salt (ATPγS, Tocris) alone or with 5 µM AR-C118925XX (AR-C, Tocris), or 10 µM cyclo(RGDfV) (cRGDfV, Sigma-Aldrich). Treatments were repeated 24 hr later. Spheres were imaged with a Zeiss Axiovert 135 light microscope at 10 x on day two after seeding. Cells were stained with 4’,6-diamidino-2-fenilindol (DAPI) (1:1000) for 10 min and imaged with a Zeiss LSM 710 confocal microscope. % Invasion was calculated by drawing an outline around the total area <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and central area <inline-formula><mml:math id="inf3"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> of the spheres with ImageJ (Fiji) and using the equation:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">%</mml:mi><mml:mi>I</mml:mi><mml:mi>n</mml:mi><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mtext> </mml:mtext></mml:mrow></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mi>x</mml:mi><mml:mn>100</mml:mn></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Results were plotted in SuperPlots by assigning different colors to repeats and superimposing a graph of the average % Invasion with a darker shade of the assigned color as described previously (<xref ref-type="bibr" rid="bib41">Lord et al., 2020</xref>).</p></sec><sec id="s4-7"><title>IncuCyte migration assay</title><p>In IncuCyte ClearView 96-well cell migration plates (Essen BioScience), 40 μL medium with 5000 cells were seeded in each well. A solution of 20 μL medium with 15 µM AR-C or 30 µM cRGDfV was added on top of the wells to achieve a final concentration of 5 µM and 10 µM, respectively. Cells were allowed to settle for 15 min at room temperature and then placed at 37 °C for pre-incubation with the treatments for another 15 min. A volume of 200 μL of medium with or without 100 µM ATP was added in the appropriate reservoir wells and the plate was placed in the IncuCyte S3 (Essen BioScience) and was monitored every 4 hr for 39 hr (average doubling time of AsPC-1 cells <xref ref-type="bibr" rid="bib9">Chen et al., 1982</xref>). Using the IncuCyte S3 2019 A software, the migration index was calculated by analyzing the average area occupied by the cells in the bottom well and was averaged with the initial average area occupied by cells in the top well.</p></sec><sec id="s4-8"><title>RNA extraction and qPCR analysis</title><p>RNA was extracted using the Monarch RNA extraction kit (New England BioLabs) as instructed by the manufacturer. The extracted RNA was quantified using a Nanodrop One Spectrophotometer (ThermoFisher Scientific). Using LunaScript RT Supermix kit (BioLabs), cDNA was prepared in a 20 μL reaction according to the manufacturer’s instructions. The resulting cDNA was used in conjunction with MegaMix-Blue and <italic>P2RY2</italic> primers (Eurogentec; Forward sequence: <named-content content-type="sequence">GCTACAGGTGCCGCTTCAAC</named-content>, reverse sequence: <named-content content-type="sequence">AGACACAGCCAGGTGGAACAT</named-content>) (<xref ref-type="bibr" rid="bib23">Hu et al., 2019</xref>) for quantitative polymerase chain reaction (qPCR) at the manufacturer’s recommended settings in a StepOnePlus Real-Time PCR System (Applied Biosystems). The relative mRNA expression was calculated using the <inline-formula><mml:math id="inf4"><mml:msup><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mo>∆</mml:mo><mml:mo>∆</mml:mo><mml:mi>C</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> method (<xref ref-type="bibr" rid="bib40">Livak and Schmittgen, 2001</xref>) and normalized to GAPDH.</p></sec><sec id="s4-9"><title>DNA-antibody coupling reaction</title><p>DNA labeling of anti-αV antibody (P2W7, Santa Cruz, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_627116">AB_627116</ext-link>) and anti-P2Y<sub>2</sub> receptor antibody (APR-010, Alomone labs, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2040078">AB_2040078</ext-link>) was performed via maleimidePEG2-succinimidyl ester coupling reaction as previously described (<xref ref-type="bibr" rid="bib59">Simoncelli et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Joseph et al., 2021</xref>). First, 30 µL of 250 mM DDT (Thermo Fisher Scientific) was added to 13 µL of 1 mM thiolated DNA sequences <named-content content-type="sequence">5′-Thiol-AAACCACCACCACCA-3′</named-content> (Docking 1), and <named-content content-type="sequence">5-Thiol-TTTCCTCCTCCTCCT-3’</named-content> (Docking 2) (Eurofins). The reduction reaction occurred under shaking conditions for 2 hrs. 30 min after the reduction of the thiol-DNA started, 175 µL of 0.8 mg/mL antibody solutions were incubated with 0.9 µL of 23.5 mM maleimide-PEG2-succinimidyl ester cross-linker solution (Sigma-Aldrich) on a shaker for 90 min at 4 °C in the dark. Prior to DNA-antibody conjugation, both sets of reactions were purified using Microspin Illustra G-25 columns (GE Healthcare) and Zeba spin desalting columns (7 K MWCO, Thermo Fisher Scientific), respectively, to remove excess reactants. Next, coupling of anti-P2Y<sub>2</sub> with DNA docking 1 and anti-αV with DNA Docking 2 was performed by mixing the respective flow-through of the columns and incubate them overnight, in the dark, at 4 °C under shaking. Excess DNA was removed via Amicon spin filtration (100 K, Merck) and antibody-DNA concentration was measured using a NanoDrop One spectrophotometer (Thermo Fisher Scientific) and adjusted to 10 µM with PBS. Likewise, spectrophotometric analysis was performed to quantify the DNA-antibody coupling ratio and found to be ∼1.2 on average for both the oligo-coupled primary antibodies.</p></sec><sec id="s4-10"><title>Cell fixation and immunofluorescence staining for DNA-PAINT imaging</title><p>Cells were seeded at 30,000 cells per channel on a six-channel glass-bottomed microscopy chamber (μ-SlideVI<sup>0.5</sup>, Ibidi) pre-coated with rat tail collagen type I (Corning). The chamber was incubated at 37 °C for 8 hr before treatments. Cells were treated with 100 μM of ATP (or the equivalent volume of PBS as control) in the medium for 1 hr and were fixed and permeabilized as described in the ‘Cell fixation and immunofluorescent staining’ section. Following permeabilization, samples were treated with 50 mM ammonium chloride solution (Avantor) for 5–10 min to quench auto-fluorescence and cells were washed 3x in PBS. Blocking was completed via incubation with 5% BSA (Merck) solution for 1 hr followed by overnight incubation at 4 °C with 1:100 dilutions of DNA labeled anti-P2Y<sub>2</sub>, and DNA labeled anti-αV antibody in blocking solution. The next day, samples were washed 3× in PBS and 150 nm gold nanoparticles (Sigma-Aldrich) were added for 15 min to act as fiducial markers for drift correction, excess of nanoparticles were removed by 3x washes with PBS. Samples were then left in DNA-PAINT imager buffer solution, prepared as described below, and immediately used for DNA-PAINT imaging experiments.</p></sec><sec id="s4-11"><title>DNA-PAINT imager solutions</title><p>A 0.1 nM P2Y<sub>2</sub> imager strand buffer solution (5-TTGTGGT-3’-Atto643, Eurofins) and a 0.2 nM αV imager strand buffer solution (5-GGAGGA-3’-Atto643, Eurofins) were made using 1x PCA (Sigma-Aldrich), 1x PCD (Sigma-Aldrich), 1x Trolox (Sigma-Aldrich), 1x PBS, and 500  mM NaCl (Merck) which facilitates the establishment of an oxygen scavenging and triplet state quencher system. Solutions were incubated for 1 hr in the dark before use. Stock solutions of PCA, PCD, and Trolox were prepared as follows: 40x PCA (protocatechuic acid) stock was made from 154 mg of PCA (Sigma-Aldrich) in 10 mL of Ultrapure Distilled water (Invitrogen) adjusted to pH 9.0 with NaOH (Avantor, Radnor Township, PA, USA). 100 x PCD (protocatechuate 3,4-dioxygenase) solution was made by adding 2.2 mg of PCD (Sigma-Aldrich) to 3.4 mL of 50% glycerol (Sigma-Aldrich) with 50 mM KCl (Sigma-Aldrich), 1 mM EDTA (Invitrogen), and 100 mM Tris buffer (Avantor). 100 x Trolox solution was made by dissolving 100 mg of Trolox in 0.43 mL methanol (Sigma-Aldrich), 0.345 mL 1 M NaOH, and 3.2 mL of Ultrapure Distilled water.</p></sec><sec id="s4-12"><title>Exchange-PAINT Imaging Experiments</title><p>Exchange DNA-PAINT imaging was performed on a custom-built total internal reflection fluorescence (TIRF) microscope based on a Nikon Eclipse Ti-2 microscope (Nikon Instruments) equipped with a 100×oil immersion TIRF objective (Apo TIRF, NA 1.49) and a Perfect Focus System. Samples were imaged under flat-top TIRF illumination with a 647 nm laser (Coherent OBIS LX, 120 mW), that was magnified with custom-built telescopes, before passing through a beam shaper device (piShaper 6_6_VIS, AdlOptica) to transform the Gaussian profile of the beam into a collimated flat-top profile. The beam was focused into the back focal plane of the microscope objective using a suitable lens (AC508-300-A-ML, Thorlabs), passed through a clean-up filter (FF01-390/482/563/640-25, Semrock), and coupled into the objective using a beam splitter (Di03-R405/488/561/635-t1-25 × 36, Semrock). Laser polarization was adjusted to circular after the objective. Fluorescence light was spectrally filtered with an emission filter (FF01-446/523/600/677-25, Semrock) and imaged on an sCMOS camera (ORCA-Flash4.0 V3 Digital, Hamamatsu) without further magnification, resulting in a final pixel size of 130 nm in the focal plane, after 2 × 2 binning. For fluid exchange, each individual chamber of the ibidi µ-SlideVI<sup>0.5</sup> was fitted with elbow Luer connector male adaptors (Ibidi) and 0.5 mm silicon tubing (Ibidi). Each imaging acquisition step was performed by adding the corresponding imager strand buffer solution to the sample. Prior to the imager exchange, the chamber was washed for 10 min with 1 x PBS buffer with 500  mM NaCl. Before the next imager strand buffer solution was added, we monitored with the camera to ensure the complete removal of the first imager strand. Sequential imaging and washing steps were repeated for every cell imaged. For each imaging step, 15,000 frames were acquired with 100ms integration time and a laser power density at the sample of 0.5 kW/cm<sup>2</sup>.</p></sec><sec id="s4-13"><title>Super-resolution DNA-PAINT image reconstruction</title><p>Both P2Y<sub>2</sub> and αV Images were processed and reconstructed using the Picasso (<xref ref-type="bibr" rid="bib58">Schnitzbauer et al., 2017</xref>) software (Version 0.3.3). The Picasso ‘Localize’ module was used to identify and localize the x, y molecular coordinates of single molecule events from the raw fluorescent DNA-PAINT images. Drift correction and multi-color data alignment were performed via the Picasso ‘Render’ module, using a combination of fiducial markers and multiple rounds of image sub-stack cross-correlation analysis. Localizations with uncertainties greater than 13 nm were removed and no merging was performed for molecules re-appearing in subsequent frames. Super-resolution image rendering was performed by plotting each localization as a Gaussian function with a standard deviation equal to its localization precision.</p></sec><sec id="s4-14"><title>Protein quantification via qPAINT analysis</title><p>To convert the list of <italic>x, y</italic> localizations into a list of <italic>x, y</italic> protein coordinates the data was further processed using a combination of DBSCAN cluster analysis, qPAINT analysis, and <italic>k-</italic>means clustering.</p><p>First, 21 randomly selected, non-overlapping, 4 × 4 µm<sup>2</sup> regions of interest (ROIs) for each type of cell and cell treatment were analyzed with a density-based clustering algorithm, known as DBSCAN. To avoid suboptimal clustering results; ROIs were selected such that they do not intersect with cell boundaries and the regions were the same for P2Y<sub>2</sub> and αV images. Single-molecule localizations within each ROIs were grouped into clusters using the DBSCAN modality from PALMsiever (<xref ref-type="bibr" rid="bib53">Pengo et al., 2015</xref>) in MATLAB (Version 2021a)(<xref ref-type="bibr" rid="bib53">Pengo et al., 2015</xref>). This clustering algorithm determines clusters based on two parameters. The first parameter is the minimum number of points (‘minPts’) within a given circle. For minPts, we chose a parameter in accordance with the binding frequency of the imager strand and acquisition frame number; in our case this was set to 10 localizations for all the experiments. The second parameter is the radius (epsilon or ‘eps’) of the circle of the cluster of single molecule localizations. This is determined by the localization precision of the super-resolved images and, according to the nearest neighbor based analysis was ca. to 10 nm for all the images.</p><p>For qPAINT analysis, we used a custom-written MATLAB (Version 2021a) code: <ext-link ext-link-type="uri" xlink:href="https://github.com/Simoncelli-lab/qPAINT_pipeline">https://github.com/Simoncelli-lab/qPAINT_pipeline</ext-link> (<xref ref-type="bibr" rid="bib27">Joseph and Simoncelli, 2023</xref>). Briefly, localizations corresponding to the same cluster were grouped and their time stamps were used to compile the sequence of dark times per cluster. All the dark times per cluster were pooled and used to obtain a normalized cumulative histogram of the dark times which was then fitted with the exponential function 1 – exp(t/τ<sub>d</sub>) to estimate the mean dark time, τ<sub>d</sub>, per cluster. The qPAINT index (<italic>q</italic><sub>i</sub>) of each cluster was then calculated as the inverse of the mean dark time, 1/τ<sub>d</sub>.</p><p>Calibration was then performed via a compilation of all qPAINT indexes obtained from the DNA-PAINT data acquired for each protein type into a single histogram. Only qPAINT indices corresponding to small clusters (i.e. clusters with a maximum point distance of 150 nm) were considered. This histogram was fitted with a multi-peak Gaussian function to determine the qPAINT index for a cluster of single molecule localizations corresponding to one protein (<italic>q</italic><sub>i1</sub>).</p><p>The calibration value obtained with this method was used to estimate the number of P2Y<sub>2</sub> and αV proteins in all the single-molecule localizations clusters identified by DBSCAN, as this corresponds to the ratio between <italic>q</italic><sub>i1</sub> and the qPAINT index of each cluster. Finally, <italic>k</italic>-means clustering was used to recover a likely distribution of the proteins’ positions in each cluster of single molecule localizations, where <italic>k</italic> is equal to the number of proteins in that cluster. This information allowed us to quantify the protein density and level of protein clustering.</p></sec><sec id="s4-15"><title>Nearest neighbor analysis</title><p>Nearest neighbor distances (NND) for P2Y<sub>2</sub> – P2Y<sub>2</sub> and αV-αV were calculated using the recovered P2Y<sub>2</sub> and αV-protein maps as described above via a custom-written MATLAB (Version 2021a) script: <ext-link ext-link-type="uri" xlink:href="https://github.com/Simoncelli-lab/qPAINT_pipeline">https://github.com/Simoncelli-lab/qPAINT_pipeline</ext-link> (<xref ref-type="bibr" rid="bib27">Joseph and Simoncelli, 2023</xref>). For colocalization analysis, the NND for each protein of one dataset with respect to the reference dataset was calculated (i.e. P2Y<sub>2</sub> - αV) using a similar MATLAB script. To evaluate the significance of the NND distributions, we randomized the positions of P2Y<sub>2</sub> and αV for the comparison of P2Y<sub>2</sub> – P2Y<sub>2</sub> and αV-αV NND distributions, respectively, and the positions of one of the two proteins for the comparison of the NND between P2Y<sub>2</sub> - αV protein distributions. The resulting histogram of the nearest neighbor distances for both the experimental data sets and the randomly distributed data was normalized using the total number of NND calculated per ROI to calculate the percentage of the population with distances smaller than a set threshold value.</p></sec><sec id="s4-16"><title>Western blotting</title><p>Cell lysates were extracted using RIPA buffer and 20 µg denatured protein per sample was loaded and separated using an 8% SDS-PAGE gel. Gels were run at 150 V for 2 hr and transferred into a nitrocellulose membrane (GE Healthcare) at 100 V for 1 hr. Following blocking with 5% milk (Sigma) in 0.1% TBS-T for 1 hr, membranes were incubated with 1:1000 dilution of antibodies against phosphorylated FAK (Tyr397, 3283, Cell Signaling, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2173659">AB_2173659</ext-link>), phosphorylated ERK 1/2 (S217/221, 9154, Cell Signaling, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2138017">AB_2138017</ext-link>), P2Y<sub>2</sub> (APR-010, Alomone Labs, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2040078">AB_2040078</ext-link>), HSC 70 (SC7298, Santa Cruz, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_627761">AB_627761</ext-link>), or α-tubulin (T5168, Sigma-Aldrich, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477579">AB_477579</ext-link>) with 5% BSA in 0.1% TBS-T overnight at 4 °C. Membranes were probed with anti-Mouse-HRP (P0447, DAKO, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617137">AB_2617137</ext-link>), or Anti-Rabbit-HRP (P0448, DAKO, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617138">AB_2617138</ext-link>) at 1:5000 in 5% milk in TBS-T for 1 hr at room temperature. Images were captured by using Luminata Forte Western HRP substrate (Millipore) and imaged with an Amersham Imager 600 (GE Healthcare).</p></sec><sec id="s4-17"><title>Statistical analysis</title><p>For the statistical analysis of the number and colocalization of DNA-PAINT images, a minimum of five 4 × 4 µm<sup>2</sup> regions obtained from AsPC-1 cells were analyzed per condition. For all experiments, normality tests were performed and the non-parametric Kruskal-Wallis test for significance was calculated. All graphs and statistical calculations of experimental data were made using Prism 9.4.1 (GraphPad).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Software, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Software, Formal analysis, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Software, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Pancreatic cancer molecular subtypes associated with purinergic gene expressions.</title><p>Purinergic genes with significantly higher expression in a specific molecular subtype have been listed below. If no significant higher expression was observed not applicable (N/A) is shown.</p></caption><media xlink:href="elife-86971-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-86971-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file, or online resources are fully referenced. Human PDAC tumour data were generated by TCGA Research Network (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/tcga">https://www.cancer.gov/tcga</ext-link>) and by the Clinical Proteomic Tumour Analysis Consortium (<ext-link ext-link-type="uri" xlink:href="https://www.proteomics.cancer.gov">https://www.proteomics.cancer.gov</ext-link>). The Genotype-Tissue Expression (GTEx) Project was used for the analysis of normal pancreatic tissue samples (<ext-link ext-link-type="uri" xlink:href="https://gtexportal.org">https://gtexportal.org</ext-link>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the Barts Pancreatic Tissue Bank (BPTB) for providing pancreatic tissue slides presented in this work. BPTB is supported by Pancreatic Cancer Research Fund and we thank all its members, in particular, Prof. Claude Chelala, Christine Hughes, Ahmet Imrali, and Amina Hughes for help, as well as Consultant Pathologist Dr. Joanne Chin-Aleong and members of Tissue Access Committee and Operations Group. We thank Dr. Ann-Marie Baker for her expertise in RNAscope experiments. This work was supported by a Medical Research Council (MRC) iCase award to PJM and RPG from Barts Charity and the MRC Doctoral Training Programme for ETB at Queen Mary University of London (Project MRC0227). NJR acknowledges the QMUL MRC Doctoral Training Program (MR/N014308/1). MDJ acknowledges support from the BBSRC (BB/T008709/1) via the London Interdisciplinary Doctoral Programme and SS acknowledges financial support from the Royal Society through a Dorothy Hodgkin fellowship (DHF\R1\191019) and a Research Grant (RGS\R2\202038). This work was supported by Cancer Research UK (CRUK) awarded to EPC and RPG (A27781) and a CRUK Centre grant to Barts Cancer Institute (A25137). Diagrams were generated using BioRender.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>DK</given-names></name><name><surname>Nones</surname><given-names>K</given-names></name><name><surname>Johns</surname><given-names>AL</given-names></name><name><surname>Patch</surname><given-names>A-M</given-names></name><name><surname>Gingras</surname><given-names>M-C</given-names></name><name><surname>Miller</surname><given-names>DK</given-names></name><name><surname>Christ</surname><given-names>AN</given-names></name><name><surname>Bruxner</surname><given-names>TJC</given-names></name><name><surname>Quinn</surname><given-names>MC</given-names></name><name><surname>Nourse</surname><given-names>C</given-names></name><name><surname>Murtaugh</surname><given-names>LC</given-names></name><name><surname>Harliwong</surname><given-names>I</given-names></name><name><surname>Idrisoglu</surname><given-names>S</given-names></name><name><surname>Manning</surname><given-names>S</given-names></name><name><surname>Nourbakhsh</surname><given-names>E</given-names></name><name><surname>Wani</surname><given-names>S</given-names></name><name><surname>Fink</surname><given-names>L</given-names></name><name><surname>Holmes</surname><given-names>O</given-names></name><name><surname>Chin</surname><given-names>V</given-names></name><name><surname>Anderson</surname><given-names>MJ</given-names></name><name><surname>Kazakoff</surname><given-names>S</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Newell</surname><given-names>F</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Wood</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wilson</surname><given-names>PJ</given-names></name><name><surname>Cloonan</surname><given-names>N</given-names></name><name><surname>Kassahn</surname><given-names>KS</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Quek</surname><given-names>K</given-names></name><name><surname>Robertson</surname><given-names>A</given-names></name><name><surname>Pantano</surname><given-names>L</given-names></name><name><surname>Mincarelli</surname><given-names>L</given-names></name><name><surname>Sanchez</surname><given-names>LN</given-names></name><name><surname>Evers</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Pinese</surname><given-names>M</given-names></name><name><surname>Cowley</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>MD</given-names></name><name><surname>Colvin</surname><given-names>EK</given-names></name><name><surname>Nagrial</surname><given-names>AM</given-names></name><name><surname>Humphrey</surname><given-names>ES</given-names></name><name><surname>Chantrill</surname><given-names>LA</given-names></name><name><surname>Mawson</surname><given-names>A</given-names></name><name><surname>Humphris</surname><given-names>J</given-names></name><name><surname>Chou</surname><given-names>A</given-names></name><name><surname>Pajic</surname><given-names>M</given-names></name><name><surname>Scarlett</surname><given-names>CJ</given-names></name><name><surname>Pinho</surname><given-names>AV</given-names></name><name><surname>Giry-Laterriere</surname><given-names>M</given-names></name><name><surname>Rooman</surname><given-names>I</given-names></name><name><surname>Samra</surname><given-names>JS</given-names></name><name><surname>Kench</surname><given-names>JG</given-names></name><name><surname>Lovell</surname><given-names>JA</given-names></name><name><surname>Merrett</surname><given-names>ND</given-names></name><name><surname>Toon</surname><given-names>CW</given-names></name><name><surname>Epari</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>NQ</given-names></name><name><surname>Barbour</surname><given-names>A</given-names></name><name><surname>Zeps</surname><given-names>N</given-names></name><name><surname>Moran-Jones</surname><given-names>K</given-names></name><name><surname>Jamieson</surname><given-names>NB</given-names></name><name><surname>Graham</surname><given-names>JS</given-names></name><name><surname>Duthie</surname><given-names>F</given-names></name><name><surname>Oien</surname><given-names>K</given-names></name><name><surname>Hair</surname><given-names>J</given-names></name><name><surname>Grützmann</surname><given-names>R</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Lawlor</surname><given-names>RT</given-names></name><name><surname>Corbo</surname><given-names>V</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Rusev</surname><given-names>B</given-names></name><name><surname>Capelli</surname><given-names>P</given-names></name><name><surname>Salvia</surname><given-names>R</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><name><surname>Munzy</surname><given-names>DM</given-names></name><name><surname>Fisher</surname><given-names>WE</given-names></name><name><surname>Karim</surname><given-names>SA</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Pilarsky</surname><given-names>C</given-names></name><name><surname>Morton</surname><given-names>JP</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Bailey</surname><given-names>U-MH</given-names></name><name><surname>Hofmann</surname><given-names>O</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Gill</surname><given-names>AJ</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic analyses identify molecular subtypes of pancreatic cancer</article-title><source>Nature</source><volume>531</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/nature16965</pub-id><pub-id pub-id-type="pmid">26909576</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Locovei</surname><given-names>S</given-names></name><name><surname>Dahl</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Pannexin membrane channels are mechanosensitive conduits for ATP</article-title><source>FEBS Letters</source><volume>572</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.07.009</pub-id><pub-id pub-id-type="pmid">15304325</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengtsson</surname><given-names>A</given-names></name><name><surname>Andersson</surname><given-names>R</given-names></name><name><surname>Ansari</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>16425</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-73525-y</pub-id><pub-id pub-id-type="pmid">33009477</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boison</surname><given-names>D</given-names></name><name><surname>Yegutkin</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Adenosine metabolism: emerging concepts for cancer therapy</article-title><source>Cancer Cell</source><volume>36</volume><fpage>582</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.10.007</pub-id><pub-id pub-id-type="pmid">31821783</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruns</surname><given-names>RF</given-names></name><name><surname>Lu</surname><given-names>GH</given-names></name><name><surname>Pugsley</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Characterization of the A2 adenosine receptor labeled by [ 3H ] NECA in rat striatal membranes</article-title><source>Molecular Pharmacology</source><volume>29</volume><fpage>331</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">3010074</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffa</surname><given-names>FM</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>West</surname><given-names>CM</given-names></name><name><surname>Miller</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene</article-title><source>British Journal of Cancer</source><volume>102</volume><fpage>428</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605450</pub-id><pub-id pub-id-type="pmid">20087356</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G</given-names></name><name><surname>Novak</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Purinergic signalling in the pancreas in health and disease</article-title><source>The Journal of Endocrinology</source><volume>213</volume><fpage>123</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1530/JOE-11-0434</pub-id><pub-id pub-id-type="pmid">22396456</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calebiro</surname><given-names>D</given-names></name><name><surname>Godbole</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Internalization of G-protein-coupled receptors: implication in receptor function, physiology and diseases</article-title><source>Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism</source><volume>32</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2018.01.004</pub-id><pub-id pub-id-type="pmid">29678288</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Horoszewicz</surname><given-names>JS</given-names></name><name><surname>Leong</surname><given-names>SS</given-names></name><name><surname>Shimano</surname><given-names>T</given-names></name><name><surname>Penetrante</surname><given-names>R</given-names></name><name><surname>Sanders</surname><given-names>WH</given-names></name><name><surname>Berjian</surname><given-names>R</given-names></name><name><surname>Douglass</surname><given-names>HO</given-names></name><name><surname>Martin</surname><given-names>EW</given-names></name><name><surname>Chu</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites</article-title><source>In Vitro</source><volume>18</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/BF02796382</pub-id><pub-id pub-id-type="pmid">7182348</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiarella</surname><given-names>AM</given-names></name><name><surname>Ryu</surname><given-names>YK</given-names></name><name><surname>Manji</surname><given-names>GA</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Extracellular ATP and adenosine in cancer pathogenesis and treatment</article-title><source>Trends in Cancer</source><volume>7</volume><fpage>731</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2021.04.008</pub-id><pub-id pub-id-type="pmid">34074623</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chorna</surname><given-names>NE</given-names></name><name><surname>Chevres</surname><given-names>M</given-names></name><name><surname>Santos-Berrios</surname><given-names>C</given-names></name><name><surname>Orellano</surname><given-names>EA</given-names></name><name><surname>Erb</surname><given-names>L</given-names></name><name><surname>González</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>P2Y2 receptors induced cell surface redistribution of alpha (V) integrin is required for activation of ERK 1/2 in U937 cells</article-title><source>Journal of Cellular Physiology</source><volume>211</volume><fpage>410</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1002/jcp.20946</pub-id><pub-id pub-id-type="pmid">17186500</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>P</given-names></name><name><surname>Gibb</surname><given-names>WJ</given-names></name><name><surname>Truitt</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Cooc</surname><given-names>J</given-names></name><name><surname>Weinkle</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>GE</given-names></name><name><surname>Jakkula</surname><given-names>L</given-names></name><name><surname>Feiler</surname><given-names>HS</given-names></name><name><surname>Ko</surname><given-names>AH</given-names></name><name><surname>Olshen</surname><given-names>AB</given-names></name><name><surname>Danenberg</surname><given-names>KL</given-names></name><name><surname>Tempero</surname><given-names>MA</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy</article-title><source>Nature Medicine</source><volume>17</volume><fpage>500</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/nm.2344</pub-id><pub-id pub-id-type="pmid">21460848</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Maggio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma</article-title><source>Pancreatology</source><volume>16</volume><fpage>995</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.pan.2016.05.393</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname><given-names>F</given-names></name><name><surname>Sarti</surname><given-names>AC</given-names></name><name><surname>Falzoni</surname><given-names>S</given-names></name><name><surname>De Marchi</surname><given-names>E</given-names></name><name><surname>Adinolfi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Extracellular ATP and P2 purinergic signalling in the tumour microenvironment</article-title><source>Nature Reviews. Cancer</source><volume>18</volume><fpage>601</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0037-0</pub-id><pub-id pub-id-type="pmid">30006588</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erb</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ockerhausen</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>Q</given-names></name><name><surname>Garrad</surname><given-names>RC</given-names></name><name><surname>Griffin</surname><given-names>K</given-names></name><name><surname>Neal</surname><given-names>C</given-names></name><name><surname>Krugh</surname><given-names>B</given-names></name><name><surname>Santiago-Pérez</surname><given-names>LI</given-names></name><name><surname>González</surname><given-names>FA</given-names></name><name><surname>Gresham</surname><given-names>HD</given-names></name><name><surname>Turner</surname><given-names>JT</given-names></name><name><surname>Weisman</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>An RGD sequence in the P2Y2 receptor interacts with αvβ3 integrins and is required for Go-mediated signal transduction</article-title><source>Journal of Cell Biology</source><volume>153</volume><fpage>491</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1083/jcb.153.3.491</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feoktistov</surname><given-names>I</given-names></name><name><surname>Ryzhov</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Goldstein</surname><given-names>AE</given-names></name><name><surname>Matafonov</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>D</given-names></name><name><surname>Biaggioni</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype</article-title><source>Hypertension</source><volume>44</volume><fpage>649</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000144800.21037.a5</pub-id><pub-id pub-id-type="pmid">15452028</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Hotson</surname><given-names>A</given-names></name><name><surname>Powderly</surname><given-names>JD</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>BGM</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Shepard</surname><given-names>DR</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Kummar</surname><given-names>S</given-names></name><name><surname>Weise</surname><given-names>AM</given-names></name><name><surname>Riese</surname><given-names>MJ</given-names></name><name><surname>Markman</surname><given-names>B</given-names></name><name><surname>Emens</surname><given-names>LA</given-names></name><name><surname>Mahadevan</surname><given-names>D</given-names></name><name><surname>Luke</surname><given-names>JJ</given-names></name><name><surname>Laport</surname><given-names>G</given-names></name><name><surname>Brody</surname><given-names>JD</given-names></name><name><surname>Hernandez-Aya</surname><given-names>L</given-names></name><name><surname>Bonomi</surname><given-names>P</given-names></name><name><surname>Goldman</surname><given-names>JW</given-names></name><name><surname>Berim</surname><given-names>L</given-names></name><name><surname>Renouf</surname><given-names>DJ</given-names></name><name><surname>Goodwin</surname><given-names>RA</given-names></name><name><surname>Munneke</surname><given-names>B</given-names></name><name><surname>Ho</surname><given-names>PY</given-names></name><name><surname>Hsieh</surname><given-names>J</given-names></name><name><surname>McCaffery</surname><given-names>I</given-names></name><name><surname>Kwei</surname><given-names>L</given-names></name><name><surname>Willingham</surname><given-names>SB</given-names></name><name><surname>Miller</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>40</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0980</pub-id><pub-id pub-id-type="pmid">31732494</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Release of adenosine triphosphate from isolated adult heart cells in response to hypoxia</article-title><source>The Journal of Physiology</source><volume>268</volume><fpage>371</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1977.sp011862</pub-id><pub-id pub-id-type="pmid">141503</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froeling</surname><given-names>FEM</given-names></name><name><surname>Mirza</surname><given-names>TA</given-names></name><name><surname>Feakins</surname><given-names>RM</given-names></name><name><surname>Seedhar</surname><given-names>A</given-names></name><name><surname>Elia</surname><given-names>G</given-names></name><name><surname>Hart</surname><given-names>IR</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and ezrin expression in tumor cells</article-title><source>The American Journal of Pathology</source><volume>175</volume><fpage>636</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2009.090131</pub-id><pub-id pub-id-type="pmid">19608876</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal complementary data sources and analysis options</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>269</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Jané-Valbuena</surname><given-names>J</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Lo</surname><given-names>CC</given-names></name><name><surname>McDonald</surname><given-names>ER</given-names></name><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Gelfand</surname><given-names>ET</given-names></name><name><surname>Bielski</surname><given-names>CM</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Andreev-Drakhlin</surname><given-names>AY</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>JM</given-names></name><name><surname>Haas</surname><given-names>BJ</given-names></name><name><surname>Aguet</surname><given-names>F</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Rothberg</surname><given-names>MV</given-names></name><name><surname>Paolella</surname><given-names>BR</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Tiv</surname><given-names>HL</given-names></name><name><surname>Gokhale</surname><given-names>PC</given-names></name><name><surname>de Weck</surname><given-names>A</given-names></name><name><surname>Mansour</surname><given-names>AA</given-names></name><name><surname>Oh</surname><given-names>C</given-names></name><name><surname>Shih</surname><given-names>J</given-names></name><name><surname>Hadi</surname><given-names>K</given-names></name><name><surname>Rosen</surname><given-names>Y</given-names></name><name><surname>Bistline</surname><given-names>J</given-names></name><name><surname>Venkatesan</surname><given-names>K</given-names></name><name><surname>Reddy</surname><given-names>A</given-names></name><name><surname>Sonkin</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Lehar</surname><given-names>J</given-names></name><name><surname>Korn</surname><given-names>JM</given-names></name><name><surname>Porter</surname><given-names>DA</given-names></name><name><surname>Jones</surname><given-names>MD</given-names></name><name><surname>Golji</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>JE</given-names></name><name><surname>Dunning</surname><given-names>CM</given-names></name><name><surname>Creech</surname><given-names>AL</given-names></name><name><surname>Warren</surname><given-names>AC</given-names></name><name><surname>McFarland</surname><given-names>JM</given-names></name><name><surname>Zamanighomi</surname><given-names>M</given-names></name><name><surname>Kauffmann</surname><given-names>A</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Maruvka</surname><given-names>YE</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Jaffe</surname><given-names>JD</given-names></name><name><surname>Lane</surname><given-names>AA</given-names></name><name><surname>Weinstock</surname><given-names>DM</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Morrissey</surname><given-names>MP</given-names></name><name><surname>Stegmeier</surname><given-names>F</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title><source>Nature</source><volume>569</volume><fpage>503</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1186-3</pub-id><pub-id pub-id-type="pmid">31068700</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedhart</surname><given-names>J</given-names></name><name><surname>Luijsterburg</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>VolcaNoseR is a web APP for creating, exploring, labeling and sharing volcano plots</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>20560</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-76603-3</pub-id><pub-id pub-id-type="pmid">33239692</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L-P</given-names></name><name><surname>Zhang</surname><given-names>X-X</given-names></name><name><surname>Jiang</surname><given-names>S-H</given-names></name><name><surname>Tao</surname><given-names>L-Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>L-L</given-names></name><name><surname>Yang</surname><given-names>M-W</given-names></name><name><surname>Huo</surname><given-names>Y-M</given-names></name><name><surname>Jiang</surname><given-names>Y-S</given-names></name><name><surname>Tian</surname><given-names>G-A</given-names></name><name><surname>Cao</surname><given-names>X-Y</given-names></name><name><surname>Zhang</surname><given-names>Y-L</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X-M</given-names></name><name><surname>Wang</surname><given-names>Y-H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>GG</given-names></name><name><surname>Sun</surname><given-names>Y-W</given-names></name><name><surname>Zhang</surname><given-names>Z-G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>1318</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2297</pub-id><pub-id pub-id-type="pmid">30420446</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibuka</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The p2y₂ receptor promotes wnt3a- and EGF-induced epithelial tubular formation by IEC6 cells by binding to integrins</article-title><source>Journal of Cell Science</source><volume>128</volume><fpage>2156</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1242/jcs.169060</pub-id><pub-id pub-id-type="pmid">25908848</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Eun</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>P2Y2 receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells</article-title><source>Breast Cancer Research</source><volume>16</volume><elocation-id>R77</elocation-id><pub-id pub-id-type="doi">10.1186/bcr3694</pub-id><pub-id pub-id-type="pmid">25156554</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>MD</given-names></name><name><surname>Tomas Bort</surname><given-names>E</given-names></name><name><surname>Grose</surname><given-names>RP</given-names></name><name><surname>McCormick</surname><given-names>PJ</given-names></name><name><surname>Simoncelli</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Quantitative super-resolution imaging for the analysis of GPCR oligomerization</article-title><source>Biomolecules</source><volume>11</volume><elocation-id>1503</elocation-id><pub-id pub-id-type="doi">10.3390/biom11101503</pub-id><pub-id pub-id-type="pmid">34680136</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>MD</given-names></name><name><surname>Simoncelli</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>QPAINT_pipeline</data-title><version designator="25bcaf2">25bcaf2</version><source>Github</source><ext-link ext-link-type="uri" xlink:href="https://github.com/simoncelli-lab/qpaint_pipeline">https://github.com/simoncelli-lab/qpaint_pipeline</ext-link></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadaba</surname><given-names>R</given-names></name><name><surname>Birke</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Andl</surname><given-names>CD</given-names></name><name><surname>Di Maggio</surname><given-names>F</given-names></name><name><surname>Soylu</surname><given-names>E</given-names></name><name><surname>Ghallab</surname><given-names>M</given-names></name><name><surname>Bor</surname><given-names>D</given-names></name><name><surname>Froeling</surname><given-names>FE</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name><name><surname>Chelala</surname><given-names>C</given-names></name><name><surname>Sasieni</surname><given-names>P</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes</article-title><source>The Journal of Pathology</source><volume>230</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1002/path.4172</pub-id><pub-id pub-id-type="pmid">23359139</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapp</surname><given-names>TG</given-names></name><name><surname>Rechenmacher</surname><given-names>F</given-names></name><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Maltsev</surname><given-names>OV</given-names></name><name><surname>Cavalcanti-Adam</surname><given-names>EA</given-names></name><name><surname>Zarka</surname><given-names>R</given-names></name><name><surname>Reuning</surname><given-names>U</given-names></name><name><surname>Notni</surname><given-names>J</given-names></name><name><surname>Wester</surname><given-names>H-J</given-names></name><name><surname>Mas-Moruno</surname><given-names>C</given-names></name><name><surname>Spatz</surname><given-names>J</given-names></name><name><surname>Geiger</surname><given-names>B</given-names></name><name><surname>Kessler</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>39805</elocation-id><pub-id pub-id-type="doi">10.1038/srep39805</pub-id><pub-id pub-id-type="pmid">28074920</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Méar</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Digre</surname><given-names>A</given-names></name><name><surname>Katona</surname><given-names>B</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Butler</surname><given-names>L</given-names></name><name><surname>Odeberg</surname><given-names>J</given-names></name><name><surname>Dusart</surname><given-names>P</given-names></name><name><surname>Edfors</surname><given-names>F</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>Arif</surname><given-names>M</given-names></name><name><surname>Altay</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ozcan</surname><given-names>M</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Mulder</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Ponten</surname><given-names>F</given-names></name><name><surname>Uhlén</surname><given-names>M</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A single-cell type transcriptomics map of human tissues</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabh2169</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abh2169</pub-id><pub-id pub-id-type="pmid">34321199</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>T</given-names></name><name><surname>An</surname><given-names>HJ</given-names></name><name><surname>Ji</surname><given-names>YG</given-names></name><name><surname>Kim</surname><given-names>OJ</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>P2Y receptors regulate proliferation of human pancreatic duct epithelial cells</article-title><source>Pancreas</source><volume>41</volume><fpage>797</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1097/MPA.0b013e31823ba3b3</pub-id><pub-id pub-id-type="pmid">22249129</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Kocher</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2023">2023</year><source>Pancreatic Cancer, BMJ Best Practice</source><publisher-name>BMJ</publisher-name><ext-link ext-link-type="uri" xlink:href="https://bestpractice.bmj.com/info/">https://bestpractice.bmj.com/info/</ext-link></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koong</surname><given-names>AC</given-names></name><name><surname>Mehta</surname><given-names>VK</given-names></name><name><surname>Le</surname><given-names>QT</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Terris</surname><given-names>DJ</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Bastidas</surname><given-names>AJ</given-names></name><name><surname>Vierra</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Pancreatic tumors show high levels of hypoxia</article-title><source>International Journal of Radiation Oncology, Biology, Physics</source><volume>48</volume><fpage>919</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1016/s0360-3016(00)00803-8</pub-id><pub-id pub-id-type="pmid">11072146</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurashima</surname><given-names>Y</given-names></name><name><surname>Amiya</surname><given-names>T</given-names></name><name><surname>Nochi</surname><given-names>T</given-names></name><name><surname>Fujisawa</surname><given-names>K</given-names></name><name><surname>Haraguchi</surname><given-names>T</given-names></name><name><surname>Iba</surname><given-names>H</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Iijima</surname><given-names>H</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Kunisawa</surname><given-names>J</given-names></name><name><surname>Kiyono</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors</article-title><source>Nature Communications</source><volume>3</volume><elocation-id>1034</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2023</pub-id><pub-id pub-id-type="pmid">22948816</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Jo</surname><given-names>YH</given-names></name><name><surname>Kirchner</surname><given-names>VA</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Kwak</surname><given-names>BJ</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>G-W</given-names></name><name><surname>Lee</surname><given-names>S-G</given-names></name><name><surname>Yoon</surname><given-names>Y-I</given-names></name><name><surname>Park</surname><given-names>G-C</given-names></name><name><surname>Tak</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HIF-1α regulates A2B adenosine receptor expression in liver cancer cells</article-title><source>Experimental and Therapeutic Medicine</source><volume>18</volume><fpage>4231</fpage><lpage>4240</lpage><pub-id pub-id-type="doi">10.3892/etm.2019.8081</pub-id><pub-id pub-id-type="pmid">31772626</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lánczky</surname><given-names>A</given-names></name><name><surname>Győrffy</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Web-based survival analysis tool tailored for medical research (kmplot): development and implementation</article-title><source>Journal of Medical Internet Research</source><volume>23</volume><elocation-id>e27633</elocation-id><pub-id pub-id-type="doi">10.2196/27633</pub-id><pub-id pub-id-type="pmid">34309564</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepzelter</surname><given-names>D</given-names></name><name><surname>Bates</surname><given-names>O</given-names></name><name><surname>Zaman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Integrin clustering in two and three dimensions</article-title><source>Langmuir</source><volume>28</volume><fpage>5379</fpage><lpage>5386</lpage><pub-id pub-id-type="doi">10.1021/la203725a</pub-id><pub-id pub-id-type="pmid">22204631</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W-H</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H-Q</given-names></name><name><surname>Tian</surname><given-names>X-X</given-names></name><name><surname>Fang</surname><given-names>W-G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>P2Y2 receptor and EGFR cooperate to promote prostate cancer cell invasion via ERK1/2 pathway</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0133165</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0133165</pub-id><pub-id pub-id-type="pmid">26182292</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jaehnig</surname><given-names>EJ</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>WebGestalt 2019: gene set analysis toolkit with revamped uis and apis</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W199</fpage><lpage>W205</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz401</pub-id><pub-id pub-id-type="pmid">31114916</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta c(t)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>SJ</given-names></name><name><surname>Velle</surname><given-names>KB</given-names></name><name><surname>Mullins</surname><given-names>RD</given-names></name><name><surname>Fritz-Laylin</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SuperPlots: communicating reproducibility and variability in cell biology</article-title><source>The Journal of Cell Biology</source><volume>219</volume><elocation-id>e202001064</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.202001064</pub-id><pub-id pub-id-type="pmid">32346721</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Ramírez</surname><given-names>AS</given-names></name><name><surname>Garay</surname><given-names>E</given-names></name><name><surname>García-Carrancá</surname><given-names>A</given-names></name><name><surname>Vázquez-Cuevas</surname><given-names>FG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The P2RY2 receptor induces carcinoma cell migration and EMT through cross-talk with epidermal growth factor receptor</article-title><source>Journal of Cellular Biochemistry</source><volume>117</volume><fpage>1016</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1002/jcb.25390</pub-id><pub-id pub-id-type="pmid">26443721</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>C</given-names></name><name><surname>Holmstrom</surname><given-names>SR</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Laise</surname><given-names>P</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Chabot</surname><given-names>JA</given-names></name><name><surname>Oberstein</surname><given-names>PE</given-names></name><name><surname>Sepulveda</surname><given-names>AR</given-names></name><name><surname>Genkinger</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Iuga</surname><given-names>AC</given-names></name><name><surname>Bansal</surname><given-names>M</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name><name><surname>Olive</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes</article-title><source>Gut</source><volume>68</volume><fpage>1034</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-317706</pub-id><pub-id pub-id-type="pmid">30658994</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffitt</surname><given-names>RA</given-names></name><name><surname>Marayati</surname><given-names>R</given-names></name><name><surname>Flate</surname><given-names>EL</given-names></name><name><surname>Volmar</surname><given-names>KE</given-names></name><name><surname>Loeza</surname><given-names>SGH</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Rashid</surname><given-names>NU</given-names></name><name><surname>Williams</surname><given-names>LA</given-names></name><name><surname>Eaton</surname><given-names>SC</given-names></name><name><surname>Chung</surname><given-names>AH</given-names></name><name><surname>Smyla</surname><given-names>JK</given-names></name><name><surname>Anderson</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Bentrem</surname><given-names>DJ</given-names></name><name><surname>Talamonti</surname><given-names>MS</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name><name><surname>Hollingsworth</surname><given-names>MA</given-names></name><name><surname>Yeh</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1168</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1038/ng.3398</pub-id><pub-id pub-id-type="pmid">26343385</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muoboghare</surname><given-names>MO</given-names></name><name><surname>Drummond</surname><given-names>RM</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Characterisation of p2y<sub>2</sub> receptors in human vascular endothelial cells using AR-C118925XX, a competitive and selective p2y<sub>2</sub> antagonist</article-title><source>British Journal of Pharmacology</source><volume>176</volume><fpage>2894</fpage><lpage>2904</lpage><pub-id pub-id-type="doi">10.1111/bph.14715</pub-id><pub-id pub-id-type="pmid">31116875</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>ER</given-names></name><name><surname>Menezes</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>JC</given-names></name><name><surname>Williams</surname><given-names>JL</given-names></name><name><surname>Alba-Castellón</surname><given-names>L</given-names></name><name><surname>Baskaran</surname><given-names>P</given-names></name><name><surname>Quétier</surname><given-names>I</given-names></name><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>Marshall</surname><given-names>JJT</given-names></name><name><surname>Rosewell</surname><given-names>I</given-names></name><name><surname>Tatari</surname><given-names>M</given-names></name><name><surname>Rajeeve</surname><given-names>V</given-names></name><name><surname>Khan</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kotantaki</surname><given-names>P</given-names></name><name><surname>Tyler</surname><given-names>EJ</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Reader</surname><given-names>CS</given-names></name><name><surname>Carter</surname><given-names>EP</given-names></name><name><surname>Hodivala-Dilke</surname><given-names>K</given-names></name><name><surname>Grose</surname><given-names>RP</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name><name><surname>Gavara</surname><given-names>N</given-names></name><name><surname>Pearce</surname><given-names>O</given-names></name><name><surname>Cutillas</surname><given-names>P</given-names></name><name><surname>Marshall</surname><given-names>JF</given-names></name><name><surname>Cameron</surname><given-names>AJM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion</article-title><source>Cell Reports</source><volume>38</volume><elocation-id>110227</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110227</pub-id><pub-id pub-id-type="pmid">35081338</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>A</given-names></name><name><surname>Attah</surname><given-names>I</given-names></name><name><surname>Al-Hroub</surname><given-names>H</given-names></name><name><surname>Namasivayam</surname><given-names>V</given-names></name><name><surname>Müller</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Discovery of p2y<sub>2</sub> receptor antagonist scaffolds through virtual high-throughput screening</article-title><source>Journal of Chemical Information and Modeling</source><volume>62</volume><fpage>1538</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.1c01235</pub-id><pub-id pub-id-type="pmid">35285230</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuzillet</surname><given-names>C</given-names></name><name><surname>Rousseau</surname><given-names>B</given-names></name><name><surname>Kocher</surname><given-names>H</given-names></name><name><surname>Bourget</surname><given-names>P</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 1: GI carcinomas</article-title><source>Pharmacology &amp; Therapeutics</source><volume>174</volume><fpage>145</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.02.028</pub-id><pub-id pub-id-type="pmid">28223233</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Burckhardt</surname><given-names>CJ</given-names></name><name><surname>Lazcano</surname><given-names>R</given-names></name><name><surname>Solis</surname><given-names>LM</given-names></name><name><surname>Isogai</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Bachoo</surname><given-names>R</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Danuser</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanical regulation of glycolysis via cytoskeleton architecture</article-title><source>Nature</source><volume>578</volume><fpage>621</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1998-1</pub-id><pub-id pub-id-type="pmid">32051585</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegatti</surname><given-names>P</given-names></name><name><surname>Raffaghello</surname><given-names>L</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Piccardi</surname><given-names>F</given-names></name><name><surname>Pistoia</surname><given-names>V</given-names></name><name><surname>Di Virgilio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e2599</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002599</pub-id><pub-id pub-id-type="pmid">18612415</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>XL</given-names></name><name><surname>Moffitt</surname><given-names>RA</given-names></name><name><surname>Torphy</surname><given-names>RJ</given-names></name><name><surname>Volmar</surname><given-names>KE</given-names></name><name><surname>Yeh</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>De novo compartment deconvolution and weight estimation of tumor samples using DECODER</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4729</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12517-7</pub-id><pub-id pub-id-type="pmid">31628300</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pengo</surname><given-names>T</given-names></name><name><surname>Holden</surname><given-names>SJ</given-names></name><name><surname>Manley</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PALMsiever: a tool to turn RAW data into results for single-molecule localization microscopy</article-title><source>Bioinformatics</source><volume>31</volume><fpage>797</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu720</pub-id><pub-id pub-id-type="pmid">25362091</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragnum</surname><given-names>HB</given-names></name><name><surname>Vlatkovic</surname><given-names>L</given-names></name><name><surname>Lie</surname><given-names>AK</given-names></name><name><surname>Axcrona</surname><given-names>K</given-names></name><name><surname>Julin</surname><given-names>CH</given-names></name><name><surname>Frikstad</surname><given-names>KM</given-names></name><name><surname>Hole</surname><given-names>KH</given-names></name><name><surname>Seierstad</surname><given-names>T</given-names></name><name><surname>Lyng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer</article-title><source>British Journal of Cancer</source><volume>112</volume><fpage>382</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.604</pub-id><pub-id pub-id-type="pmid">25461803</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahib</surname><given-names>L</given-names></name><name><surname>Wehner</surname><given-names>MR</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name><name><surname>Nead</surname><given-names>KT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estimated projection of US cancer incidence and death to 2040</article-title><source>JAMA Network Open</source><volume>4</volume><elocation-id>e214708</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.4708</pub-id><pub-id pub-id-type="pmid">33825840</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedl</surname><given-names>J</given-names></name><name><surname>Crevenna</surname><given-names>AH</given-names></name><name><surname>Kessenbrock</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>JH</given-names></name><name><surname>Neukirchen</surname><given-names>D</given-names></name><name><surname>Bista</surname><given-names>M</given-names></name><name><surname>Bradke</surname><given-names>F</given-names></name><name><surname>Jenne</surname><given-names>D</given-names></name><name><surname>Holak</surname><given-names>TA</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name><name><surname>Sixt</surname><given-names>M</given-names></name><name><surname>Wedlich-Soldner</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lifeact: a versatile marker to visualize F-actin</article-title><source>Nature Methods</source><volume>5</volume><fpage>605</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1220</pub-id><pub-id pub-id-type="pmid">18536722</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Winzer</surname><given-names>R</given-names></name><name><surname>Rissiek</surname><given-names>A</given-names></name><name><surname>Ricklefs</surname><given-names>I</given-names></name><name><surname>Meyer-Schwesinger</surname><given-names>C</given-names></name><name><surname>Ricklefs</surname><given-names>FL</given-names></name><name><surname>Bauche</surname><given-names>A</given-names></name><name><surname>Behrends</surname><given-names>J</given-names></name><name><surname>Reimer</surname><given-names>R</given-names></name><name><surname>Brenna</surname><given-names>S</given-names></name><name><surname>Wasielewski</surname><given-names>H</given-names></name><name><surname>Lauten</surname><given-names>M</given-names></name><name><surname>Rissiek</surname><given-names>B</given-names></name><name><surname>Puig</surname><given-names>B</given-names></name><name><surname>Cortesi</surname><given-names>F</given-names></name><name><surname>Magnus</surname><given-names>T</given-names></name><name><surname>Fliegert</surname><given-names>R</given-names></name><name><surname>Müller</surname><given-names>CE</given-names></name><name><surname>Gagliani</surname><given-names>N</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>5911</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-26134-w</pub-id><pub-id pub-id-type="pmid">34625545</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzbauer</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>MT</given-names></name><name><surname>Schlichthaerle</surname><given-names>T</given-names></name><name><surname>Schueder</surname><given-names>F</given-names></name><name><surname>Jungmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Super-resolution microscopy with DNA-PAINT</article-title><source>Nature Protocols</source><volume>12</volume><fpage>1198</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.024</pub-id><pub-id pub-id-type="pmid">28518172</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoncelli</surname><given-names>S</given-names></name><name><surname>Griffié</surname><given-names>J</given-names></name><name><surname>Williamson</surname><given-names>DJ</given-names></name><name><surname>Bibby</surname><given-names>J</given-names></name><name><surname>Bray</surname><given-names>C</given-names></name><name><surname>Zamoyska</surname><given-names>R</given-names></name><name><surname>Cope</surname><given-names>AP</given-names></name><name><surname>Owen</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multi-color molecular visualization of signaling proteins reveals how C-terminal src kinase nanoclusters regulate T cell receptor activation</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108523</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108523</pub-id><pub-id pub-id-type="pmid">33357425</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>S</given-names></name><name><surname>Jungmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Up to 100-fold speed-up and multiplexing in optimized DNA-PAINT</article-title><source>Nature Methods</source><volume>17</volume><fpage>789</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-0869-x</pub-id><pub-id pub-id-type="pmid">32601424</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Synnestvedt</surname><given-names>K</given-names></name><name><surname>Furuta</surname><given-names>GT</given-names></name><name><surname>Comerford</surname><given-names>KM</given-names></name><name><surname>Louis</surname><given-names>N</given-names></name><name><surname>Karhausen</surname><given-names>J</given-names></name><name><surname>Eltzschig</surname><given-names>HK</given-names></name><name><surname>Hansen</surname><given-names>KR</given-names></name><name><surname>Thompson</surname><given-names>LF</given-names></name><name><surname>Colgan</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Ecto-5’-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia</article-title><source>The Journal of Clinical Investigation</source><volume>110</volume><fpage>993</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1172/JCI15337</pub-id><pub-id pub-id-type="pmid">12370277</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>E</given-names></name><name><surname>Jun</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Park</surname><given-names>G-C</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>G-W</given-names></name><name><surname>Lee</surname><given-names>S-G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells</article-title><source>The Journal of International Medical Research</source><volume>44</volume><fpage>1234</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1177/0300060516662135</pub-id><pub-id pub-id-type="pmid">27807254</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>MH</given-names></name><name><surname>Nowak</surname><given-names>NJ</given-names></name><name><surname>Loor</surname><given-names>R</given-names></name><name><surname>Ochi</surname><given-names>H</given-names></name><name><surname>Sandberg</surname><given-names>AA</given-names></name><name><surname>Lopez</surname><given-names>C</given-names></name><name><surname>Pickren</surname><given-names>JW</given-names></name><name><surname>Berjian</surname><given-names>R</given-names></name><name><surname>Douglass</surname><given-names>HO</given-names><suffix>Jr</suffix></name><name><surname>Chu</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Characterization of a new primary human pancreatic tumor line</article-title><source>Cancer Investigation</source><volume>4</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.3109/07357908609039823</pub-id><pub-id pub-id-type="pmid">3754176</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>YH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A nanoengineering approach for immobilization</article-title><source>ACS Nano</source><volume>2</volume><fpage>2374</fpage><lpage>2384</lpage><pub-id pub-id-type="doi">10.1021/nn800508f</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>W98</fpage><lpage>W102</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id><pub-id pub-id-type="pmid">28407145</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teoh</surname><given-names>CM</given-names></name><name><surname>Tam</surname><given-names>JKC</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Integrin and GPCR crosstalk in the regulation of ASM contraction signaling in asthma</article-title><source>Journal of Allergy</source><volume>2012</volume><elocation-id>341282</elocation-id><pub-id pub-id-type="doi">10.1155/2012/341282</pub-id><pub-id pub-id-type="pmid">23056062</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulapurkar</surname><given-names>ME</given-names></name><name><surname>Schäfer</surname><given-names>R</given-names></name><name><surname>Hanck</surname><given-names>T</given-names></name><name><surname>Flores</surname><given-names>RV</given-names></name><name><surname>Weisman</surname><given-names>GA</given-names></name><name><surname>González</surname><given-names>FA</given-names></name><name><surname>Reiser</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Endocytosis mechanism of P2Y2 nucleotide receptor tagged with green fluorescent protein: clathrin and actin cytoskeleton dependence</article-title><source>Cellular and Molecular Life Sciences</source><volume>62</volume><fpage>1388</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1007/s00018-005-5052-0</pub-id><pub-id pub-id-type="pmid">15924261</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varet</surname><given-names>H</given-names></name><name><surname>Brillet-Guéguen</surname><given-names>L</given-names></name><name><surname>Coppée</surname><given-names>J-Y</given-names></name><name><surname>Dillies</surname><given-names>M-A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SARTools: a deseq2- and edger-based R pipeline for comprehensive differential analysis of RNA-Seq data</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0157022</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0157022</pub-id><pub-id pub-id-type="pmid">27280887</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Lake</surname><given-names>R</given-names></name><name><surname>Guedez</surname><given-names>L</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cd97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells</article-title><source>Blood</source><volume>105</volume><fpage>2836</fpage><lpage>2844</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-07-2878</pub-id><pub-id pub-id-type="pmid">15576472</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Tu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial protein UQCRC1 is oncogenic and a potential therapeutic target for pancreatic cancer</article-title><source>Theranostics</source><volume>10</volume><fpage>2141</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.7150/thno.38704</pub-id><pub-id pub-id-type="pmid">32089737</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>SC</given-names></name><name><surname>Buffa</surname><given-names>FM</given-names></name><name><surname>Silva</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Valentine</surname><given-names>HR</given-names></name><name><surname>Turley</surname><given-names>H</given-names></name><name><surname>Shah</surname><given-names>KA</given-names></name><name><surname>Cox</surname><given-names>GJ</given-names></name><name><surname>Corbridge</surname><given-names>RJ</given-names></name><name><surname>Homer</surname><given-names>JJ</given-names></name><name><surname>Musgrove</surname><given-names>B</given-names></name><name><surname>Slevin</surname><given-names>N</given-names></name><name><surname>Sloan</surname><given-names>P</given-names></name><name><surname>Price</surname><given-names>P</given-names></name><name><surname>West</surname><given-names>CML</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers</article-title><source>Cancer Research</source><volume>67</volume><fpage>3441</fpage><lpage>3449</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3322</pub-id><pub-id pub-id-type="pmid">17409455</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Grol</surname><given-names>MW</given-names></name><name><surname>Grutter</surname><given-names>PH</given-names></name><name><surname>Dixon</surname><given-names>SJ</given-names></name><name><surname>Komarova</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Modeling interactions among individual P2 receptors to explain complex response patterns over a wide range of ATP concentrations</article-title><source>Frontiers in Physiology</source><volume>7</volume><elocation-id>294</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2016.00294</pub-id><pub-id pub-id-type="pmid">27468270</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms</article-title><source>Cancer Letters</source><volume>519</volume><fpage>289</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2021.07.024</pub-id><pub-id pub-id-type="pmid">34302921</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>A</given-names></name><name><surname>Díaz</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The impact of hypoxia in pancreatic cancer invasion and metastasis</article-title><source>Hypoxia</source><volume>2</volume><fpage>91</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.2147/HP.S52636</pub-id><pub-id pub-id-type="pmid">27774469</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86971.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>White</surname><given-names>Richard M</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>In this manuscript, the authors address an important and urgent question: what molecular mechanisms drive the invasive behavior of pancreatic adenocarcinoma? Because these tumors have such a strong propensity for invasion and metastasis, identifying actionable targets is of high importance. Using a combination of in silico and in vitro modeling, they identify a role for purinergic G-protein coupled receptor P2Y<sub>2</sub> as a critical node in mediating PDAC invasion, and they find that blocking the crosstalk between P2Y<sub>2</sub> and αV integrins via a peptide inhibitor blocks PDAC invasion, which may have clinical utility. Thus their study provides insights into both the basic biology of PDAC but also identifies a new target.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86971.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86971.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>1. General Statements [optional]</p></disp-quote><p>We are grateful to the reviewers for highlighting the novelty of the mechanism we describe for P2Y2 in driving RGD-binding integrin-dependent invasion, and acknowledging its potential in cancer therapy. We thank the reviewers for their valuable and detailed comments, which have allowed us to prepare a significantly stronger and clearer manuscript.</p><disp-quote content-type="editor-comment"><p>2. Point-by-point description of the revisions</p><p>Reviewer #1 (Evidence, reproducibility and clarity (Required)):</p><p>Summary</p><p>The study identifies P2Y2 as a purinergic receptor strongly associated with hypoxia, cancer expression and survival. A link is found between P2Y2-integrin interaction and cancer invasion, highlighting this as a novel therapeutic target. The mechanism is interesting and general well explored.</p></disp-quote><p>We thank the reviewer for acknowledging the novelty of the therapeutic target presented in this work.</p><disp-quote content-type="editor-comment"><p>Minor comments</p><p>As P2Y2 is highly expressed by other cell types found with tumours, including vascular endothelium and leukocytes, the authors should reflect on this as a confounding factor in the analysis of adrenocarcinoma gene expression analysis. I appreciate the RNAscope work may resolve this issue to some extent.</p></disp-quote><p>We agree that P2Y2 is known to be expressed in other cell types. RNAscope did not show convincing staining in PDAC normal adjacent tissue (was similar to negative staining), perhaps due to the challenging nature of pancreatic tissue with respect to RNA degradation. We have resolved this issue by including single cell RNA-seq of normal human pancreas for P2Y2 from Protein Atlas (Sup. Figure 2B), which shows expression in several cell types, mainly endocrine cells, and macrophages. We now mention this in line 142 : “P2Y2 is known to be expressed at low levels in normal tissues but interestingly RNAscope did not detect this. This data suggest (1) the lower limits of the technique compounded by the challenge of RNA degradation in pancreatic tissue and (2) supports that in tumour tissue where it was detected there was indeed overexpression of P2Y2, in line with the bioinformatic data. Interrogating single cell P2Y2 RNA expression in normal PDAC from proteinatlas.org (Karlsson et al., 2021), expression was found at low levels in several cells types, for example in endocrine cells and macrophages (Sup. Figure 2B).”</p><disp-quote content-type="editor-comment"><p>Major comments</p><p>The authors correctly identify that the level of ATP in the tumour microenvironment can be very high, typically 100uM or so. However, these concentrations are supramaximal for P2Y2 activation, at which ATP has an approximate EC50 of 100nM. Coupled with the fact that many cell types, including cancer cells, constitutively secrete ATP, there is an opportunity to explore the effects of lower ATP concentrations in some assays, or provide some concentration-response relationship to give more confidence of P2Y2-dependent effects.</p></disp-quote><p>We thank the reviewer for raising this point and we agree that 100 μm can be a high concentration, albeit one that is frequently used throughout the literature. We have now included a concentration-response relationship (Sup. Figure 2D) showing that ATP causes cytoskeletal changes that are P2Y2 dependent most prominently at 100 uM, the concentration that, as the reviewer has also corroborated, is similar to the concentration of ATP found in tumours.</p><disp-quote content-type="editor-comment"><p>Also, the authors describe the use of cancer cells where P2Y2 has been knocked out using CRISPR. Does this KO have an effect on cancer invasion? The effect of ARC should be absent in these cells and give confidence the effects of ARC are P2Y2-dependent, as some off-target effects of this antagonist have been reported. To explore the influence of constitutive P2Y2 activity, the authors should explore the effects of ARC alone in some assays.</p></disp-quote><p>We agree that including more AR-C only experiments would be informative, so we have included a 3D sphere invasion assay with our CRISPR cell line treated with and without AR-C that shows no effect in invasion (<italic>p</italic> = 0.4413) (Sup. Figure 3J). We have now also included images of AsPC-1 cells transfected with Lifeact, showing no changes in morphology with AR-C only (Sup. Figure 2E). We apologise for missing a ‘+’ in one of the supplementary figures which shows AR-C only in AsPC-1 cells has no effect on its own.</p><p>The effects of the CRISPR cell line in invasion are shown in Figure 3F, showing a significant reduction (<italic>p</italic> = 0.0005) in invasion.</p><disp-quote content-type="editor-comment"><p>The title of the manuscript implies extracellular ATP drives cancer invasion, though in my opinion this statement is not fully explored. Though ATP/UTP are applied at supramaximal concentrations for P2Y2 activation, the influence of ATP in the cell culture microenvironment without exogenous application is not explored. One would predict that scavenging extracellular ATP with apyrase would negatively impact invasiveness and the proximity of integrin and P2Y2 without ATP/UTP application if constitutively secreted ATP is involved. Pharmacological manipulation of ectonucleotidase activity is an alternative. Experimental route to explore this.</p></disp-quote><p>We agree and have changed the title of our article to “Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion”. Our 3D sphere experiments with the CRISPR cell line show a reduction in invasion without exogenous application of ATP, which we also see to a lesser extent in our siRNA P2Y2 cell line. We have tested our sphere model with apyrase but unfortunately, the buffer used for apyrase to work is not compatible with our gel composition. Pharmacological manipulation would be a very good alternative if the cells used expressed high levels of CD39 or PANX1, which unfortunately they don’t. We hypothesise that most basal extracellular ATP in our 3D spheres comes from hypoxic areas that cause cell death, just as is postulated for tumours.</p><disp-quote content-type="editor-comment"><p>Immunoprecipitation experiments of native proteins would be more convincing data that P2Y2 and integrin physically interaction, as opposed to being in close proximity. This would also overcome artifacts of interaction that can be attributed to receptor overexpression.</p></disp-quote><p>We attempted immunoprecipitation experiments but unfortunately ran into several technical difficulties, including the anti-αV antibody working poorly for Western blot. Immunoprecipitation of these proteins has been reported by others (PMID: 25908848), supporting the proposed interaction.</p><p>DNA-PAINT super resolution microscopy allows for quantification of nanoscale distances, and we used this to calculate the distances where physical interaction occurs. The possibility of this close proximity being by chance is accounted for in the computational nearest neighbour distance calculation by calculating points randomly distributed. This random distribution calculation also helps in overcoming artifacts of interaction due to overexpression, as the random distributed points are the same number of points as the proteins detected in each condition for each region of interest. Importantly, we also performed DNA-PAINT in using untransfected AsPC-1 thus endogenous levels (no receptor overexpression or alteration) and saw similar results (Sup. Figure 4A-D), thus we are confident of the interactions reported.</p><p>Finally, we alter the RGD motif, which underpins the physical interaction, and see significant changes that match observations in previous publications using the P2Y2 agonist UTP, mentioned in the discussion: Line 398 “Following ATP stimulation, the number of P2Y2 proteins at the plasma membrane decreased significantly after one hour, implying receptor internalisation, in line with previous work showing P2Y2 at the cell surface was reduced significantly after one hour of UTP stimulation (Tulapurkar et al., 2005).” and Line 408: “P2Y2 affecting cell surface redistribution of αV integrin has been reported, with αV integrin clusters observed after 5 min stimulation with UTP (Chorna <italic>et al.</italic>, 2007)”</p><disp-quote content-type="editor-comment"><p>It is currently not clear what the mechanistic relationship between P2Y2 activity, P2Y2-integrin proximity and RGD motif is. Do the authors suggest the RGD domain becomes exposed upon receptor activation? The mechanism is not fully articulated in the discussion.</p></disp-quote><p>We apologise for any lack of clarity in our postulated mechanism, we have now included a more detailed explanation of the mechanism in the discussion : Line 417 “We speculate that by reducing the ability of integrins to bind to the RGD of P2Y2, through receptor internalisation, RGE mutation or through cRGDfV treatment, there is less RGD-triggered integrin endocytosis, hence less integrin recycling and an increase of integrins at the cell surface.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Significance (Required)):</p><p>General assessment: A novel mechanism is presented for therapeutic intervention of cancer. The study relies on supramaximal concentrations of agonist and overexpressed receptors. Role of endogenous P2Y2 not fully explored. The study lacks in vivo evidence of the importance of this mechanisms. Cell developed in the study could be used in mouse models to explore effect on tumour growth.</p><p>Advance: Integrin and P2Y2 interactions are already documented but not in context of cancer.</p><p>Audience: basic research</p></disp-quote><p>We thank the reviewer for crediting this work as a novel mechanism for therapeutic intervention of cancer. We trust that the new data provided (as discussed above) have resolved the concerns of the reviewer as we now have provided an explanation for the concentrations used. We do rely on overexpressed receptors for a small portion of our experiments, however, all experiments with overexpressed receptors were then tested in cells with endogenous expression of P2Y2 and used pharmacological means to show the same behaviour. We have now clarified this. We have also included in the discussion a sentence about the mouse experiment performed by Hui et al. with regards to reduced tumour growth when targeting P2Y2: Line 365: “Combination treatment of subcutaneous xenografts of AsPC-1 or BxPC-3 cells with the P2Y2 antagonist AR-C together with gemcitabine significantly decreased tumour weight and resulted in increased survival compared to placebo or gemcitabine monotherapy control (Hu et al., 2019).”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Evidence, reproducibility and clarity (Required)):</p><p>Summary:</p><p>Considering the fact that most PDAC are characterized by a high level of extracellular purines content, authors decided to study the expression of the 23 genes coding for membrane proteins involved in the binding or transport of purines in available PDAC transcriptomic cohorts. This approach led to the identification of P2Y2, a GPCR, as the best predictor for the worst survival of patients. Using in vitro models, they show that P2Y2 expression is associated with increased invasion capacity of pancreatic cancer cells and that this pro-invasive effect is dependent on the interaction of P2Y2 with αV integrin via the RGD motif.</p><p>Major comments:</p><p>It is not clear to me why authors decided at one point to perform a GSEA comparing low and high mRNA expression of P2Y2 and why they decided to focus on the potential interaction of P2Y2 with integrin αV. As a GPCR, activation of P2Y2 leads to the activation of several downstream signaling pathways that may directly impact the adhesion, migration, and invasion properties of cells. Moreover, despite the presence of the RGD motif in P2Y2, it is not excluded that it may bind (maybe more efficiently) to other &quot;cell adhesion&quot; molecules.</p></disp-quote><p>We apologise if the link between the GSEA figure and focusing on the potential integrin interaction was not clear. We have now performed GSEA using the panther gene set library, which includes a “Integrin signalling pathway” gene set. This was the top ranked gene set in both cohorts and we have substituted the GSEA figure for this instead (Figure 2D). We trust that the narrative of the manuscript and our rationale to pursue the importance of integrin interaction is now clear.</p><p>We agree with the reviewer and believe that P2Y2 may bind to other molecules important in cell adhesion. We studied integrin interactions due to the clear relationship of P2Y2 and integrins in patient data, which was not as evident with other binding partners. Furthermore, this relationship is unexplored in cancer and offers novel therapeutic strategies.</p><disp-quote content-type="editor-comment"><p>Similarly, if αV can regulate P2Y2 signaling, what about the regulation of αV signaling pathways by P2Y2? αV integrin has to bind to a β subunit and, depending on the identity of the β subunit, may have distinct regulations and so different impact on cell invasion. How P2Y2 can interfere with these α/β ratios?</p></disp-quote><p>We thank the reviewer for this comment, and have now included western blots showing the impact of P2Y2 treatment on integrin signalling through FAK and ERK (Figure 5). We agree that the β subunit may have distinct regulation and outputs, but this is outwith the scope of our current study.</p><disp-quote content-type="editor-comment"><p>While it has been shown in other studies, in this work, there is no real proof of the interaction between P2Y2 and αV. Only in Figure 4I, where the authors look at the NND &lt;20nm between both proteins, we can see that only 1 to 2 % of αV is in close proximity with P2Y2, which seems very low.</p></disp-quote><p>We thank the reviewer for raising this point as it has made us realise that our chosen NND of &lt;20 nm, in an attempt of being cautious, consistant, and only select true physical interaction was too strict for some conditions. We have adjusted this to the maximum NND required for the proteins to physically touch based on individual protein and antibody dimensions (Sup. Figure 5A). The resulting changes are &lt;50 nm for P2Y2-αV, &lt;20 nm for αV-αV and &lt;40 nm for P2Y2-P2Y2, giving more realistic percentages for each condition. We then verified this range using the NND histograms now included in the manuscript, which additionally provide information about the distribution of the NNDs in each protein-protein dynamic (Sup. Figure 5B). One important point is that integrins are part of a large number of protein complexes and interact with many proteins, hence only a small percentage will be interacting with P2Y2.</p><p>Surprisingly, in the absence of ATP, P2Y2 RGE mutant, which should no more interact with αV, show a 2 to 3 fold more vicinity to αV compared to WT P2Y2. How can the authors explain this?</p><p>We agree that this is a surprising, but robust discovery. By altering the RGD motif, there may be less RGD-triggered integrin endocytosis, leading to increased integrins at the surface. We have included this hypothesis in the discussion in Line 417. The RGE mutation has less affinity to integrins, meaning it still retains some ability to bind to integrins. Hence by chance, a higher number of integrins will result in a higher number of interactions with the RGE. We are planning to interrogate the internalisation dynamics in a future study.</p><disp-quote content-type="editor-comment"><p>For DNA-PAINT experiments, the authors only focus on membrane proteins whose amounts are balanced by internalization, recycling and export from internal compartment. As claimed, but not demonstrated by the authors, interaction of P2Y2 and αV may interfere with all these steps, thereby increasing or decreasing the cell surface expression of both proteins. Hence, it would be useful to (1) control proteins levels by western blot, especially for the overexpressed P2Y2, to be sure that they are the same, (2) block internalization and/or export to decipher the important steps.</p><p>In fact, all these main questions are raised by the authors in the end of the discussion but so far, they only show that the RGD motif has an impact on the biological role of P2Y2 (cell invasion) and on the membrane dynamic of αV and itself.</p></disp-quote><p>We thank the reviewer for the suggestions:</p><p>1) In the course of our attempts to perform co-IP for P2Y2 and αV we could confirm that P2Y2 expression levels were equivalent (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>), but the problems with anti-αV antibodies prevented completion of the experiment. We also show IF staining showing similar levels of P2Y2 for both overexpressed conditions (Sup. Figure 3K).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Immunoprecipitation of P2Y<sub>2</sub> showing similar P2Y<sub>2</sub> levels in AsPC-1 P2Y<sub>2</sub><sup>CRISPR</sup> cells transfected with P2Y<sub>2</sub><sup>RGD</sup> or P2Y<sub>2</sub><sup>RGE</sup> and treated with 100 µM of ATP or control for 1 hour.</title><p>Antibody used: anti-P2Y<sub>2</sub> (APR-010, Alomone Labs).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86971-sa2-fig1-v2.tif"/></fig><p>2) As the reviewer highlights, in this work we have focused on the role of P2Y2 in PDAC invasion and have looked at single-molecule resolution membrane dynamics of αV and P2Y2. The different steps of P2Y2 and integrin αV interactions in internalisation, recycling and export are certainly interesting to study but beyond the scope of the current manuscript and in our future aims. We include these ideas in the discussion as suggestions for future research and as a possible explanation for the dynamics observed.</p><disp-quote content-type="editor-comment"><p>Figure 2A, authors use RNAscope in order to reveal P2Y2 mRNA expression and distribution in tumor versus normal tissue from 2 patients. They rather show the protein expression, using the antibody they used in other experiments, by standard IHC and in a higher number of patients, including short and long survival, to confirm that the results they obtain by bioinformatics study of transcriptomic data are real.</p></disp-quote><p>We now explicitly mention a paper (PMID: 30420446) that performed IHC of P2Y2 in 264 patients showing that P2Y2 was predominantly found in the tumour area, matching our bioinformatics study: Line 141 “matching our findings from larger publicly available cohorts, including P2Y2 IHC data from 264 patients in the Renji cohort (Hu et al., 2019).” and Line 359 “These observations were supported by published immunohistochemical staining of 264 human PDAC samples, showing that P2Y2 localised predominantly in cancer cells in human PDAC…”</p><disp-quote content-type="editor-comment"><p>Some figure legends are incorrectly numbered or described, such as the figure 4.</p></disp-quote><p>We apologise for the incorrectly described figures in figure 4, this has now been corrected.</p><disp-quote content-type="editor-comment"><p>Minor comments:</p><p>Can we reasonably talk about OMIC while studying 23 genes? In fact, as described by Timothy A. J. Haystead in 2006 (PMID: 16842150) the purinome is constituted of about 2000 genes coding for proteins binding to purines (including all kinases for example). Author should redefine they pool of genes as perhaps purines receptors/transporter?</p></disp-quote><p>We agree with the reviewer and have redefined the pool of genes to ‘purinergic signalling genes’ or ‘(part of the) extracellular purinome’.</p><disp-quote content-type="editor-comment"><p>P2Y2 and ADORA2B associated with worse survival while P2Y11 and ADORA2A are associated with better survival (Figure 1B). Would it be more interesting to understand why proteins of the same family act in opposite ways?</p></disp-quote><p>We have now included text exploring this idea in the discussion. Both P2Y2 and ADORA2B show increased expression with HIF-1α and/or hypoxia and the inverse happens with ADORA2A, for example. Line 352: “Adenosine A2B receptor requires larger agonist concentrations for activation compared to other receptors in the same family, such as adenosine A2A (Bruns, Lu and Pugsley, 1986; Xing et al., 2016), and receptor expression has been reported to increase when cells are subjected to hypoxia (Feoktistov et al., 2004). Moreover, HIF-1α has been shown to upregulate A2B and P2Y2 expression in liver cancer (Tak et al., 2016; Kwon et al., 2019).”</p><disp-quote content-type="editor-comment"><p>Figure 1C, any value for the correlation with Survival? Cause this is not so obvious in the figure.</p></disp-quote><p>We agree this correlation needs strengthening with a numeric value, we have now included a Kaplan-Meier curve of high vs low Winter hypoxia score PDAC patients showing significantly lower survival with higher Winter hypoxia score (Sup. Figure 1B).</p><disp-quote content-type="editor-comment"><p>Regarding the correlation of P2Y2 and ADORA2B with hypoxia scores, any HIF1 responsive element in promoter? What happens regarding the expression level of these genes when cells are transferred to low oxygen conditions?</p></disp-quote><p>We thank the reviewer for these questions. The relationship of P2Y2 and ADORA2B with hypoxia and/or HIF-1α has been explored in other publications which are now cited in the discussion. Line 356: “Moreover, HIF-1α has been shown to upregulate A2B and P2Y2 expression in liver cancer (Tak <italic>et al.</italic>, 2016; Kwon <italic>et al.</italic>, 2019).” Of note, a HIF1-α responsive element has been reported for A2B, but as yet not for P2Y2.</p><disp-quote content-type="editor-comment"><p>Figure 4 E to M are too small.</p></disp-quote><p>We apologise and have now increased the size of the graphs and the figure.</p><disp-quote content-type="editor-comment"><p>In Supp Figure 4, what are the &quot;Non-altered AsPC-1 cells&quot;?</p></disp-quote><p>We apologise for the confusion that may have arisen from calling normal AsPC-1 cells “Non-altered AsPC-1 cells”. We have changed this to ‘Normal AsPC-1 cells (untransfected and unchanged P2Y2 expression).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Significance (Required)):</p><p>Strengths: All the data shown are experimentally and statistically strong.</p><p>Limitations: This study remains largely descriptive with no real molecular mechanism that could at least partially explain the biological role of P2Y2 regarding cell invasion.</p><p>Advance: Limited</p></disp-quote><p>We thank the reviewer for noting the experimental strength of the paper.</p><p>After the suggested changes, including integrin signalling experiments, and strengthening our DNA-PAINT results, the molecular mechanism presented in this work has been strengthened and clarified significantly. These changes have also helped greatly in the mechanistic explanation of the role of P2Y2 in cell invasion.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Evidence, reproducibility and clarity (Required)):</p><p>The authors concentrate on the members of the purinome and attempt to identify members of the pathway that are especially relevant for PDAC biology, especially invasion and metastatic spread. Using the in silico analysis of transcriptome data from publicly available PDAC patient cohorts, the authors identify P2Y2 as being the most prominent in terms of cancer cell expression and with highest impact on patient survival. The authors than take an effort in functional characterization of P2Y2 and demonstrate that downregulation/deletion of P2Y2 leads to abrogation of ATP activated invasion in hanging drop spheroid model system in a very reasonable and scientifically good way. Finally, the authors postulate that the P2Y2 actions go over interaction with integrin AlphaV and modulations of the cellular cytoskeleton and show via DNA PAINT that a direct interaction of the 2 molecules. The hypothesis is experimentally elaborated in a sound way mostly using cell culture as a system.</p><p>The study is solid communicated, the number of experiments seems to be fine. For my understanding, the study relies much on mRNA data (gene expression in cell lines and patient samples), I would suggest providing evidence on protein level what might have been challenging due to potential lack of specific antibody.</p></disp-quote><p>We thank the reviewer for acknowledging our experimentally elaborated hypothesis and our solid communication of the study. As mentioned before, we now explicitly mention a paper (PMID: 30420446) that performed IHC of P2Y2 in 264 patients showing that P2Y2 was predominantly found in the tumour area, matching our bioinformatics study.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Significance (Required)):</p><p>To strengthen the hypothesis experimentally, I would suggest the experiments listed below:</p><p>Figure 1: The authors took a solid bioinformatic effort and analyzed expression of different genes of the purinome pathway in different PDAC patient and cell gene expression databases. In this part, the authors rely a lot on correlation of hypoxia and define high hypoxia scores and low hypoxia scores from previously published datasets. Although hypoxia surely plays an important biological condition in the PDAC, I am not sure I get the connection between purinome pathway and hypoxia. Few sentences give a broad introduction about hypoxia-purinome connection in the discussion part of the manuscript, but I think the readership would benefit from more specific statements (which drug, which hypoxic target, which system-mouse/human/cells, what was the exact discovery) and connect those specific statements to the work that has been done here.</p></disp-quote><p>We agree with the reviewer that the study can benefit from more information about the hypoxia-purinergic signalling link. Hence, we have now included more detailed explanations of how hypoxia and purinergic signalling are related in the discussion, giving more information about the cell types and the exact discovery. Line 338: “Purinergic signalling has been associated classically with hypoxia and immune function in cancer (Di Virgilio et al., 2018). One of the first reports of hypoxia inducing ATP release in cells identified an increase of extracellular ATP in rat heart cells when kept in hypoxic conditions (Forrester and Williams, 1977). PDAC is a highly hypoxic cancer, with high levels of ATP reported in the tumour interstitial fluid of human and mouse PDAC tissues compared to healthy tissues (Hu et al., 2019).”</p><disp-quote content-type="editor-comment"><p>Do the authors attempt to state here that hypoxic PDACs are those with worse prognosis and more aggressive and thus try to associate members of the purine pathway with those &quot;worse&quot; PDACs? Surprisingly, there is relatively little knowledge about hypoxia in PDAC and I would not suggest using it in this context as a predictor. Reports do suggest that hypoxia forces the emerging of resistant phenotypes but if the authors want to use hypoxic signatures, they have to fortify better (with literature) why do they choose hypoxia and what is the hypothesis that connects hypoxia to purinome, what makes this connection worth investigating.</p></disp-quote><p>We thank the reviewer for raising the question of PDAC and worse prognosis with hypoxia. We have now included a Kaplan-Meier curve of high vs low Winter hypoxia score PDAC patients showing significantly lower survival with higher Winter hypoxia score (Sup. Figure 1B). The significant link with poor survival shown with hypoxia and the inclusion of more detailed explanation of the links with hypoxia and purinergic signalling proteins (mentioned above), now clarify the reasoning for investigating this connection.</p><disp-quote content-type="editor-comment"><p>I find the statement &quot;hypoxia in tumor core&quot; a bit tricky, acute and chronic hypoxia can occur anywhere in the tumor, to my knowledge there are no reports saying only the tumor core suffers from hypoxia in PDAC. PDAC being especially rich in stroma in all of its parts is probably more prone to overall hypoxia and not only in tumor core.</p></disp-quote><p>We agree that “hypoxia in tumour core” can be a tricky statement. We have changed “tumour core” to tumour cell compartment and have cited data that demonstrate hypo-vascularisation found in the juxta-tumoural stroma, due to PDAC cells inhibiting angiogenesis (PMID: 27288147). This paper supports our hypothesis of distribution of oxygen being reduced in the tumour area. Hence why we hypothesise that purinergic genes would be preferentially expressed in the tumour area: Line 112 “We hypothesised that genes related to high hypoxia scores would be expressed preferentially in the tumour cell compartment, as PDAC cells inhibit angiogenesis, causing hypo-vascularisation in the juxta-tumoural stroma (Di Maggio et al., 2016).”</p><p>We would like to clarify that we do not believe that only the tumour core suffers from hypoxia, we hypothesise that there is more hypoxia in the tumour cell areas. Although there are no reports of only the tumour core suffering from hypoxia, there is evidence of the tumour epithelial region of the cancer having a greater range of hypoxia (1-39%) compared to the stromal (1-13%) (PMID: 26325106). Moreover, all our analyses point to most purinergic genes differentially expressed in patients with high hypoxic scores being also related to cancer cells and the tumour region. These bioinformatic results linking certain genes like <italic>P2RY2</italic> and <italic>ADORA2B</italic> with hypoxia are also supported in published work cited in the discussion (Line 354 and 356).</p><disp-quote content-type="editor-comment"><p>I would suggest that the authors rely on published subtyping of PDAC</p><p>patient cohorts (Collisson et al., 2010; Bailey et al; Moffit et al., 2015; Chan-Sen-Yue, 2020)</p><p>and correlate the expression of purinome genes with the QM/basal-like PDAC subtype that has been confirmed multiple times as the &quot;bad predictor&quot; and use those subtypes for correlation with purinome pathway members. In figure 1E is also shown that P2RY2 is high in expression in basal-like subtype.</p></disp-quote><p>We thank the reviewer for this suggestion and have included the subtyping of patients in the PAAD-TCGA cohort in Sup. Table 1 and added comments about the genes related to the different subtypes in the text: Line 88 “In the Bailey model, most genes were related to the Immunogenic subtype except for NT5E, ADORA2B, PANX1 and P2RY2, which related to Squamous (Bailey et al., 2016). Collisson molecular subtyping showed several purinergic genes associated mostly to quasimesenchymal and exocrine subtypes (Collisson et al., 2011). The Moffit subtypes were not strongly associated with purinergic genes except for ADA, NT5E, P2RY6, P2RY2 and PANX1 associated with the Basal subtype (Moffitt et al., 2015).” and Line 345 “Expression of most purinergic genes was associated predominantly with immune cells, immunogenic PDAC subtype and low hypoxia scores (Figure 1C, E). In contrast, expression of genes correlated with worse survival and hypoxia (<italic>PANX1</italic>, <italic>NT5E</italic>, <italic>ADORA2B</italic> and <italic>P2RY2</italic>) was associated with tumour cells and the squamous PDAC subtype, correlating with hypoxia, inflammation and worse prognosis (Bailey <italic>et al.</italic>, 2016).”</p><p>We did not include the subtyping of Chan-Sen-Yue, 2020, due to the similarities with Moffit and the lack of correlation of basal/classical types with purinergic signalling genes as many of them are not expressed in cancer cells.</p><disp-quote content-type="editor-comment"><p>Figure 2: In further course of the paper the authors elaborate on possible functions of P2RY2 in PDAC. Although the mRNA data is pretty elaborate, the RNA SCOPE ISH has been performed on only 3 (!) patient PDAC samples. To demonstrated the mRNA is really found in tumor and not in normal adjacent tissue or stroma, I would strongly suggest to increase the number of samples here. The authors should perhaps try to co-localize ISH signals with IF/IHC for some other cancer cell marker, e.g. PanCK or GATA6/KRT81 in human samples to differentiate basal-like from classical samples; if possible, I would even suggest to perform immunohistochemistry instead of RNA scope and confirm the presence of the receptor. If there is an issue with the antibody availability, please state so in the manuscript so that it is clear to the readers why mRNA expression is favored over protein.</p></disp-quote><p>We thank the reviewer for these suggestions.</p><p>RNAscope was used to verify our transcriptomic bioinformatic results of location of expression P2Y2 in the tumour from publicly available data of 60 pairs of laser microdissection of PDAC epithelial and stromal tissue and the PAAD TCGA deconvolution of 177 patients. We have experienced issues with RNAscope due to the RNA degradation in pancreatic tissue and other technical difficulties which unfortunately led to only having 3 samples showing staining with the positive control. All three successful samples showed P2Y2 expression located in cancer cells. The images presented show the location of P2Y2 RNA expression in the tumour region, which was the aim of the RNAscope experiment.</p><p>RNAscope only captures mRNA expression above a specific threshold, and we are aware that P2Y2 will be expressed in other cell types in the normal adjacent as seen in the deconvolution. We have now included in supplementary single cell RNAseq data of normal PDAC tissue to counteract this issue (Sup. Figure 2B).</p><p>We also cite a publication that has performed P2Y2 IHC in 264 patients and showed that P2Y2 protein expression was predominantly shown in the epithelial tumour region (PMID: 30420446), hence staining of P2Y2 in a high number of patients has already been performed: Line 359 “These observations were supported by published immunohistochemical staining of 264 human PDAC samples, showing that P2Y<sub>2</sub> localised predominantly in cancer cells in human PDAC”</p><p>As shown in Figure 1 E, P2Y2 is associated with basal and classical tumour cells, not just exclusively to basal, hence the staining to differentiate subtypes is not pertinent to the focus of this paper.</p><disp-quote content-type="editor-comment"><p>The GSEA data indicated that high P2Y2 expression relates to processes of adhesion/ECM/cytoskeleton organization where the authors draw the conclusion (based also on published data mostly on neuronal/astrocyte work) that P2Y2 may interact with integrins over the RGD domain and thus contribute to invasion an migration. Since this is a very important assumption, I would strongly suggest to expand the experiments of figure 2E and 2G on at least 2 more PDAC cell line, if possible include some with originally epithelial morphology (eg. HPAFII, HPAC…).The visualization of filaments can be done with common IF staining, eg. phalloidin, no need for stable expression.</p></disp-quote><p>Perhaps the reviewer missed Sup. Figure 2F, where data from Figure 2G are recapitulated in 3 different cell lines. We support the idea of the reviewer in including epithelial morphology cells, hence we added an extra cell line to have 2 cells with epithelial morphology, BxPC-3 and CAPAN-2.</p><p>We have tried repeating the experiment in Figure 2E in epithelial cells, but the way the epithelial cells grow in clusters (Sup. Figure 2F) make it very difficult to evaluate the morphology of individual cells and get quantifiable results. Nonetheless, we show phenotypic similarities of BxPC-3 to AsPC-1 cells in the invasion assays.</p><disp-quote content-type="editor-comment"><p>I would also be in favor of investigating the expression of EMT markers upon ATP stimulation.</p></disp-quote><p>We thank the reviewer for the suggestion, although feel this is out of scope for our study. There have been recent controversies with reference to EMT and cancer metastasis (PMID:31666716) but more importantly we see changes in cell morphology 1 hour after ATP treatment, indicating it is not/not just EMT.</p><disp-quote content-type="editor-comment"><p>How was 100µM/5µM chosen as a working concentration?</p></disp-quote><p>We have now included figures showing different concentrations of ATP (Sup. Figure 2D) and AR-C (Sup. Figure 2E) to illustrate how the concentrations were selected based on the greatest change in morphology for ATP and the full recovery of original cell morphology for AR-C.</p><disp-quote content-type="editor-comment"><p>AsPC-1 is also known as the cell line that gladly migrates and invades, usually used in metastatic modeling of PDAC. Would be interesting to see if another cell line that is not that migrative (HPAF II) presents the same effect…</p></disp-quote><p>This is an interesting point, although we haven’t performed experiments with low migrative cells, later on the work, invasion assays with the epithelial cell line BxPC-3, which has a very different migrative nature, presented the same effect (Sup. Figure 3G, F). We also perform invasion assays with PANC-1 cells, which also recapitulate an invasive phenotype when transfected with P2Y2.</p><disp-quote content-type="editor-comment"><p>Is treatment with ATP inducing expression of P2RY2 maybe? What is happening with Intergrin expression upon ATP treatment? Since the hypothesis is that extracellular ATP is driving the invasion, I would certainly suggest to investigate if ATP treatment induces expression of P2RY2 in a time and dose dependent manner.</p></disp-quote><p>We thank the reviewer for this suggestion. We have now changed the title to “Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion”, hence shifting from a focus on extracellular ATP and focusing on the effects of the RGD motif in invasion.</p><disp-quote content-type="editor-comment"><p>Figure 3:</p><p>The authors made very good efforts here to provide functional evidence that P2Y2 is really involved and essential for ATP induced invasion in PDAC cells. They performed an 3D hanging drop spheroid model for invasion in co-culture with stellate cells and show that ATP treatment leads to invasive behavior that is than blocked by addition of P2Y2 antagonist or RGD blocking peptides. Although stellate cells are a nice add-on, keeping in mind the very complex tissue micro-environment of the PDAC, I don't rate the presence of stellate cells here as essential. Are the results the same when experiments are performed without stellate cells?</p></disp-quote><p>We thank the reviewer for raising this point, as it has allowed us to clarify that the stellate cells are crucial for this assay to work as they are essential for the formation of the cancer spheres due to their matrix deposition. We have included the hanging drop with and without stellate cells to illustrate this point (Sup. Figure 3A)</p><disp-quote content-type="editor-comment"><p>EMT markers increase upon ATP stimulation, do not increase under siRNA downregulation of P2Y2?</p></disp-quote><p>As mentioned above, we thank the reviewer for the comment, but we are not focusing on EMT, given the rapidity of the phenotype we observe.</p><disp-quote content-type="editor-comment"><p>Furthermore, the authors downregulate the P2Y2 using the siRNA/CRISPR-Cas9 approach and confirm that the P2Y2 is really involved in the invasive spread also using the specific RGD block. Experiments in the figure 3 are fairly done and provide functional evidence for the hypothesis. I would suggest that for clarity reasons on every panel (A, B,C…) is written which cell line is used (mostly Aspc1) and for the siRNA experiment I would suggest writing directly on the figure the time points (48h-72h post transfection) and shortly explain in the text why was mRNA evaluated as the measure of siRNA efficacy and not the protein? Probably the antibody problem, though western-blot applicable antibodies are available.</p></disp-quote><p>We thank the reviewer for acknowledging that the experiments in figure 3 provide functional evidence for our hypothesis. We agree with the reviewer and for clarity have included the cell line in each panel and the time point post transfection. We now include a Western blot showing protein levels in the siRNA P2Y2 treatment (Sup. Figure 3I).</p><disp-quote content-type="editor-comment"><p>Furthermore, for providing higher impact, I would encourage the experiments to be performed (at least in part) in a PDAC cell line with epithelial morphology (eg. HPAF II or any other that expresses the P2Y2 to a reasonable level).</p></disp-quote><p>We agree that performing this experiment with an epithelial morphology cell line provides higher impact, hence why we performed the experiment in BxPC-3 cell lines, perhaps missed in Sup. Figure 3G and H. We now highlight that they are epithelial-like in the text.</p><disp-quote content-type="editor-comment"><p>Figure 5: By using the DNA-PAINT method, the authors demonstrated that integrin av and P2Y2 physically interact in the cell membrane over the RGD domain and these interactions are essential for ATP induced P2Y2 mediated invasion in Aspc1 cells. The performed work seems plausible, however, I leave the technical evaluation of this experiment to experts in the field.</p><p>General suggestion:</p><p>I believe the work would benefit from a clinical/patient perspective if the authors show by immunohistochemistry in PDAC tissue samples that P2Y2 is localized at the invasive front/or metastasis. Is there a surrogate marker that can be used to label ATP rich regions in the tumor, are those regions at the invasive front? Are the P2Y2 positive cells those cells at the invasive front?</p></disp-quote><p>This is an interesting suggestion but immunostaining has already been performed on a large cohort of 264 PDAC patients (PMID: 30420446) and expression was consistent throughout the tumour cells.</p></body></sub-article></article>